



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Association of metabolically healthy overweight/obesity with none of metabolic abnormalities with incident hyperglycemia in Chinese adults: a 5-year cohort study

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-087307
Article Type:	Original research
Date Submitted by the Author:	09-Apr-2024
Complete List of Authors:	Gao, Qin; Jining Medical College, Liang, Boya; Binzhou Medical University Li, Hongmin; Jining Medical University Xie, Ruining; Jining Medical University Xu, Yaru; Jining Center for Disease Control and Prevention Tong, Yeqing; Hubei Provincial Center for Disease Control and Prevention Jiang , Shunli; Jining Medical University
Keywords:	Obesity, DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Association of metabolically healthy overweight/obesity with none of metabolic abnormalities with incident hyperglycemia in Chinese adults: a 5-year cohort study

Qin Gao¹, Boya Liang², Hongmin Li¹, Ruining Xie¹, Yaru Xu³, Yeqing Tong^{4*}, Shunli Jiang^{1*}

* Yeqing Tong and Shunli Jiang contributed equally to this paper.

1 Public Health School, Jining Medical University, Jining, China

2 Public Health School, Binzhou Medical University, Yantai, China

3 Jining Center for Disease Control and Prevention, Jining, China

4 Hubei Provincial Center for Disease Control and Prevention, Wuhan, China

Corresponding Author: Shunli Jiang, 33 Jianshe Road, Rencheng District, Jining, 272000, China. E-mail addresses: utopianjiang@163.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To explore whether metabolically healthy overweight (MHOW) and/or metabolically healthy obesity (MHO) increase hyperglycemia risk in a Chinese population with a board age range.

Design: Retrospective cohort study with health check from 2010 to 2016.

Setting and participants: A total of 47391 metabolically healthy participants with none of metabolic abnormalities were selected from 32 sites and 11 cities in China. Cox-proportional hazard model was employed to estimate the association of MHOW and MHO for incident hyperglycemia.

Primary and secondary outcome measures: hyperglycemia include incident diabetes and IFG. Diabetes was diagnosed with fasting blood glucose ≥ 7.0 mmol/L and/or on self-report during follow-up. The FPG level of IFG was from 5.6 to 6.9 mmol/L.

Results: With an average follow-up of 3.06 years, 5274 participants (11.13%) developed hyperglycemia over 144,804 person-years, with an incidence rate of 36.42 per 1000 persons-years. Adjusted model revealed a higher risk of incident hyperglycemia in the MHOW group (HR=1.23, 95% CIs: 1.16 to 1.30) and the MHO group (HR=1.49, 95% CI: 1.33 to 1.67) compared with the MHNW group. With 1 unit increase of BMI, the risk of hyperglycemia increased by 6% (HR = 1.06, 95% CI: 1.04 to 1.07). The stratified analyses and interaction tests showed the robustness of the association, and there were a stronger association in women (*P* for interaction <0.001).

Conclusions: The MHOW and MHO phenotypes were positively associated with higher risk of hyperglycemia in this population. And the association was particularly stronger in women. Early screening and weight management can help lower the hyperglycemia incidence in metabolically healthy population.

Strengths and limitations of this study

1. This retrospective cohort study was representative of Chinese population with a large sample size and a broad age range.
2. The metabolically healthy status was defined strictly based on NCEP ATP-III criteria with none of metabolic abnormalities.
3. The index of WC was not measured at baseline, we cannot predict the risk of hyperglycemia among abdominally obese individuals.
4. The other confounding factors, such as physical activity and dietary factors were not included in analysis.

Introduction

About 537 million adults across the world were diagnosed with diabetes mellitus, and over 90% was type 2 diabetes mellitus (T2DM)¹. In addition, prediabetes has become an epidemic phenomenon. In 2021, 6.2% of the adult population in the world are impaired fasting glucose (IFG) or 10.6% are impaired glucose tolerance (IGT)¹. Among Chinese adults, the prevalence of diabetes and prediabetes was high and increased from 2013 to 2018^{2, 3}, with the prevalence was about 12.4% and 38.1% in 2018³.

Global obesity prevalence increased gradually since the early 1980s⁴, which is one of the critical risk factors of diabetes mellitus. However, some obese individuals, who do not have other major cardiovascular risk factors, named metabolically healthy obesity (MHO). However, the MHO phenotype likely evolves towards metabolically unhealthy obesity, which may increase cardiovascular disease risk and mortality over time.

Importantly, the definition of MHO is inconsistent at present. The most common definition of MHO is based on the criteria provided by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III)⁵, and most definitions require fewer than two of criteria factors except for waist circumference (WC)⁶. A systematic review reported that MHO prevalence was from 6% to 75%, and this may vary due to unified definition and social demographic⁷. In a Chinese adult population, the MHO prevalence varied between 13.6% when using the homeostasis model assessment criteria, 11.4% using the Chinese Diabetes Society criteria, and 10.3% using ATP-III criteria⁸.

Compared with the metabolic healthy normal weight (MHNW) individuals, whether the risk of diabetes increase of MHO population is interesting. There were some studies indicated that MHO individuals were not at increased risk for diabetes compared with MHNW individuals^{9, 10}, however, other studies showed that MHO was associated with an increased risk of diabetes^{11, 12}. Furtherly, the association was not significant with the MHO defined with none of metabolic abnormalities^{11, 12}. In addition, the inconsistent results were correlated with the different age range of the population. The participants were middle-aged under 60 years in most of the previous studies^{9, 10, 13-15}, however, in China the studies mainly focused on the elderly individuals^{11, 12, 16}.

Therefore, we illustrated the association of hyperglycemia (including diabetes and IFG) among the young, middle-aged and elderly metabolically healthy individuals without any metabolic abnormalities of the ATP-III criteria from a large cohort Chinese population.

Methods

Subjects

Raw data were download from the "DATADRYAD" database (www.datadryad.org) provided by Chen et al.¹⁷. This secondary analysis did not violate the authors rights, as the authors waived the copyright¹⁷.

The information of 211,833 individuals was introduced in detail by Chen et al.¹⁷. As this present study focus on metabolically healthy status, we further excluded participants with (1) BMI < 18.5 kg/m² (n=12081); (2) systolic blood pressure (SBP) ≥130 mmHg and/or diastolic blood pressure (DBP) ≥ 85 mmHg or no available blood pressure value (n=61440); (3) fasting plasma glucose (FPG) ≥ 5.6 mmol/L (n=1618); (4) triglyceride (TG) ≥ 1.7 mmol/L or no available TG (n=28504); (5) high density lipoprotein cholesterol (HDL-C) ≤ 1.04 mmol/L (men) or ≤ 1.29 mmol/L (women) or no available HLD-C (n=60799), and finally 47391 individuals were included. The flowchart is shown in Fig. 1.

Data collection

As described in the original study, the basic information was collected by questionnaire, and anthropometric data were measured in a standardized way. Blood pressure was measured by standard mercury sphygmomanometers. Fasting blood was collected to measure glucose levels, TG, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), HDL-C, aspartate transaminase (AST), and the alanine transaminase (ALT) by an autoanalyzer (Beckman 5800).

Definitions of obesity, metabolic health

Body weight was categorized based on BMI to normal weight (18.5-23.9 kg/m²), overweight (24.0-27.9 kg/m²), and obese (≥ 28.0 kg/m²). WC was not used due to the collinearity with BMI¹⁴. Metabolically healthy status was defined based on NCEP ATP-III criteria⁵ as the absence of any metabolic abnormalities, which include: (1) systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg; (2) TG ≥ 1.7 mmol/L; (3) FPG ≥ 5.6 mmol/L; (4) HDL-C ≤ 1.03 mmol/L in men or ≤ 1.29 mmol/L in women. According to BMI categories and metabolically healthy status, the participants were divided into three phenotypes: (1) MHNW, (2) MHOW, (3) MHO.

Outcome Measures

Hyperglycemia (dichotomous variable: 0 = non- Hyperglycemia, 1 = Hyperglycemia). In this study, hyperglycemia include incident diabetes and IFG. Diabetes was diagnosed with fasting blood glucose ≥7.0 mmol/L and/or on self-report during follow-up. The FPG level of IFG was from 5.6 to 6.9 mmol/l based on the American Diabetes Association criteria¹⁸.

Covariates

The screening of covariates is based on previous literature^{11, 12, 16, 17, 19, 20}, which included: (1) continuous variables: age, ALT, AST, LDL-C, TC, blood urea nitrogen (BUN), and serum creatinine (SCr); (2) categorical variables: gender, smoking status, drinking status, and family history of diabetes.

Missing Data Processing

The missing data for LDL-C: 26 (0.17%), ALT: 35 (0.23%), AST: 8,120 (53.75%), BUN: 354 (2.34%), SCr: 113 (0.75%), drinking status: 10,473 (69.33%), and smoking status: 10,473 (69.33%), respectively. Multiple imputation was used for missing continuous variables in the present study. This module uses a chain algorithm and uses R's MI package for multiple interpolation. Treated as categorical variables for the missing data of categorical variables²¹.

Statistical Analysis

Basic characteristics were presented as mean \pm SD or percentage. One-way ANOVA or Kruskal-Wallis test for continuous variables and χ^2 test for categorical variables were analyzed for group comparisons.

Kaplan-Meier survival method and Cox-proportional hazard model were employed to estimate the association of MHOW and MHO for incident hyperglycemia. According to the STROBE statement recommendation²², the crude, minor- and full adjustment models were presented. In addition, a restricted cubic spline (RCS) model was constructed to explore the dose-response relationship between BMI and hyperglycemia prevalence.

We performed subgroup analyses to verify the modification effects of age, gender and family history of diabetes on the correlation of BMI with hyperglycemia. And the interaction effects were conducted between BMI categories and the corresponding subgroup variable. Sensitivity analysis was performed by considering diabetes or IFG as outcome separately.

All data were analyzed with R software (version 4.3.3) and Empower Stats (version 4.1). A two-sided P -value < 0.05 was set as statistically significant.

Patient and public involvement

Patients were not involved in the design, or conduct, or reporting, or dissemination plans of our research, because this program was a retrospective study.

Results

Basic characteristics of the study participants

A total of 47391 metabolically healthy participants (47.66% male) were finally included. The mean age and BMI were 40.95 ± 11.05 years and 22.48 ± 2.59 kg/m², respectively. During 3.06 ± 0.95 years follow-up period, 5274 participants (11.13%) developed hyperglycemia. The characteristics stratified by BMI categories and the status of blood glucose were presented in Table 1 and Supplementary Table 1. Participants with higher BMI generally had higher FPG, SBP, DBP, TG, TC, LDL-C, ALT, AST, BUN, SCr, lower HDL-C, and had a higher percentage of male, current smoker and current drinker ($P < 0.001$; Table 1). During follow-up, all of the characteristics of hyperglycemic participants were different with participants without hyperglycemia ($P < 0.05$; Supplementary Table 1).

The univariate analysis for hyperglycemia in the metabolically healthy population

Supplementary Table 2 showed that higher age, BMI, FPG, DBP, SBP, TG, TC, LDL, AST, ALT, current drinker and smoker, and lower HDL-C were the risk factors of hyperglycemia. The females have a lower risk than the males. In Fig. 2, the Kaplan-Meier curve showed higher hazards were determined among MHOW and MHO (log-rank test, $P < 0.001$).

The association of MHOW/MHO and hyperglycemia risk among metabolically healthy participants

In metabolically healthy participants, 5274 individuals developed hyperglycemia over 144,804 person-years of follow-up, and the overall rate of hyperglycemia was 36.42 per 1000 person-years. The rate of hyperglycemia was 29.35 in MHNW group, 54.07 in MHOW group, and 72.24 in MHO group per 1000 person-years, respectively.

The hazard ratio (HR) and 95% confidence intervals (CI) of the BMI categories on the incidence of hyperglycemia were listed in Table 2. In the crude model, compared with MHNW participants, the risk of hyperglycemia in MHOW group increased 85% (HR = 1.85, 95% CI:1.75 to 1.97), and the risk in MHO group increased 163% (HR = 2.63, 95% CI:2.35 to 2.95), respectively. After adjusted for age, gender, and the family history of diabetes, the HR (95% CI) in MHOW group and MHO group was 1.51 (1.42, 1.60) and 2.10 (1.88, 2.36). Furtherly, after adjusting all the covariates, the relationship still exists, as the HR (95% CI) was 1.23 (1.16-1.30) for MHOW and 1.49 (1.33-1.67) for MHO, *P* for trend <0.001. By taking BMI as a continuous variable, we furtherly analyzed the correlation between BMI and hyperglycemia risk. The risk of incident of hyperglycemia increased by 6% (HR = 1.06, 95% CI:1.04 to 1.07, *P* < 0.001) with 1 unit increase of BMI.

The RCS model showed the risk of hyperglycemia increased gradually with increasement of BMI, even the significant relationship was nonlinear (*P*< 0.001, *P*-nonlinearity = 0.039, Supplementary Fig.1).

Subgroup analyses and sensitivity analyses

The stratified analyses and interactions effects were performed and the results were summarized in Table 3. The additive interactions between MHOW/MHO and hyperglycemia risk were observed in gender, and stronger correlation was found in female participants. However, no significant interaction was found in age or family history of diabetes.

In addition, the sensitivity analyses of the risk of diabetes and IFG were furtherly performed to inspect the robustness of the results (Supplementary Table 3). After adjusted for the covariates, the HR (95% CI) of incident diabetes was 1.39 (1.05-1.85) for MHOW and 2.91 (1.94-4.37) for MHO, *P* for trend <0.001; the HR (95% CI) of IFG was 1.23 (1.16, 1.31) for MHOW and 1.49 (1.32,1.68) for MHO, *P* for trend <0.001.

Discussion

The association between the BMI categories and incident hyperglycemia in the metabolically healthy population was examined in this cohort study. Compared with the MHNW group, the risk of hyperglycemia gradually increased in the MHOW group and MHO group. And, an increasing trend of incidence of hyperglycemia with a higher BMI. This present study suggests that the presence of MHOW/MHO, even with the absence of metabolic risk factors, significantly increased the incidence of hyperglycemia. MHOW and/or MHO should not be treated as a healthy status, and weight management maybe an effective way for prevention of hyperglycemia and its related metabolic diseases among MHOW or MHO individuals.

The BioSHaRE-EU Healthy Obese Project have shown that the MHO prevalence of was 7%-28% for women, and 2%-19% for men²³. The MHO prevalence ranged from 4.2% in a Chinese cohort⁸ to 13.3% among Asian Indians²⁴ and 28.5% in African Americans²⁵. In this study, the prevalence of MHOW (21.93%) and MHO (3.25%) were lower than previous reports, due to metabolically healthy status was strictly defined with none of metabolic abnormalities.

Wu et al. have shown the positive effect of MHO on diabetes based on large

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

numbers of epidemiological studies worldwide⁶. However, the correlation was weakened when metabolically healthy status was defined with none of metabolic abnormalities. Evidently, the incidence of diabetes increased by 35-67% with one metabolic abnormality addition among metabolically healthy participants²⁶. For example, Feng et.al found that the risk of diabetes was increased in the MHO individual among 49,702 older people, but the association was not significantly when MHO was characterized with no ATP-III risk factors¹¹. In addition, Wei et.al found the increased risk of diabetes for MHO, but the elevated incidence was not statistically significant among MHO individuals with none of metabolic abnormalities in Dongfeng Tongji cohort study¹².

However, we still found a higher risk of hyperglycemia in MHOW group and MHO group as metabolically healthy status defined without any metabolic abnormalities in our study. What's more, we found the positive association of MHOW/MHO phenotype on diabetes and IFG, respectively. In consistent, compared with MHNW young men, the risk of diabetes among those MHOW or MHO individuals with absence of metabolic abnormalities were 1.89 and 3.88 times²⁶. The results were inconsistent may be related with the following reasons. Firstly, the difference of age may partly explain the inconsistent results. The age of the individuals was 63.2 years¹¹ and 66 (63-71) years¹², while the mean age in our study was 40.95± 11.05 years. The young MHO adults conferred a higher hyperglycemia risk, because they are more likely to develop different metabolic abnormalities in the short term, while the middle-aged MHO population who were likely overweight or obese for years without developing diabetes or metabolic disorders. In addition, as is known, the "metabolically health" status without metabolic abnormalities becomes less with aging²³, so the numbers of MHOW and MHO in the former studies^{11, 12} were obviously less than this present study.

Notably, interaction between gender and BMI categories on incident hyperglycemia was significant, as the risk of women was higher than men. This result was in line with some^{27, 28}, but not all previous studies^{29, 30}. A cohort study found that the diabetes risk and IFG in obese women was higher²⁷. Similarly, the other prospective case-cohort study observed that, particularly in women, WC was strongly associated with T2DM²⁸. However, the greater HRs of diabetes in men with per SD increasement of BMI than in women (*P* for heterogeneity < 0.001) was found based on China Kadoorie Biobank study³⁰. The previous studies have shown that obesity as the risk factor of diabetes was more common and stronger in women^{31, 32}.

The mechanism of positive association between BMI and hyperglycemia incidence in metabolically healthy population still remains unclear. However, to some content, the correlation may be interpreted by the increased inflammation and insulin resistance of MOW and/or MHO phenotypes. As we all know, overweight and/or obesity have been always chronic low-grade inflammatory status, especially in insulin sensitive tissues, like liver, muscle and adipose tissues³³. There was evidence showed that, even in MHO subjects, chronic inflammation plays critical role in diabetes development^{34, 35}. Adipose tissue pro-inflammatory macrophages accumulation and infiltration was the most important cause of chronic inflammation³⁶. Pro-inflammatory cytokines

mainly secreted from macrophages, such as tumor necrosis factor (TNF- α) and interleukin-1 beta (IL-1 β), can trigger various signal pathway to induce insulin resistance. Critical signal pathways include TNF- α / IKK β /NF- κ B, and TLR4/NLRP3/caspase-1/IL-1 β , which impair insulin action and modulate pancreas β -cell mass and function³⁷.

Study strengths and limitations

Apart from a large sample size and a broad age range, this study has several strengths. The metabolically healthy individuals were included without any metabolic risk factors, as to reveal the independent role of BMI and hyperglycemia risk. Furtherly, sensitivity analyses, subgroup analyses and interaction effects were examined to attest the reliability and stability of the results. There are several limitations of our study. Firstly, the index of WC was not measured at baseline, we cannot combine WC and BMI to distinguish people with abdominally obesity and cannot predict the risk of hyperglycemia among abdominally obese individuals. In addition, the hyperglycemia prevalence may be underestimated as the random plasma glucose and/or postprandial plasma glucose level were not collected. Finally, although numerous confounding factors were included, some potential factors may exist, such as physical activity and dietary factors.

To conclude, this study demonstrated that MHOW and MHO were independently positively associated with risk of incident hyperglycemia in absolutely metabolically healthy adults, and the correlation was particularly stronger in women. Considering the unsteady characteristics of metabolically healthy/obese phenotypes, these findings stress that early screening and weight control was necessary to lower hyperglycemia risk and to promote population health.

Acknowledgments

Thank for the contribution of the field investigators and the cooperation of the participants in the Rich Healthcare Group. And thank for sharing the database by the authors of Chen et al.

Footnotes

Contributions

QG, QTY and SLJ: study design. QG, BYL and HML: data cleaning and analysis. QG, BYL, HML and RNX: result interpretation. QG, BYL, HML and RNX: manuscript writing. BYL and HML: manuscript editing. All authors approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (82204031), Natural Science Foundation of Shandong Province (ZR2021QH188), and the Lin He's Academician Workstation of New Medicine and Clinical Translation in Jining Medical University (JYHL2022MS13).

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data availability statement

Data sharing statement Extra data can be accessed via the Dryad data repository at

<http://datadryad.org/withthedoi:10.5061/dryad.ft8750v>.

Ethics statements

Patient consent: Not required.

Ethics approval: This study was approved by the Rich Healthcare Group Review Board, and the information was retrieved retrospectively.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

1. International Diabetes Federation. IDF Diabetes Atlas 10th Edition [M]. 2021.

2. Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. *JAMA* 2017;317:2515-23.doi.org/10.1001/jama.2017.7596

3. Wang L, Peng W, Zhao Z, et al. Prevalence and Treatment of Diabetes in China, 2013-2018. *JAMA* 2021;326:2498-506.doi.org/10.1001/jama.2021.22208

4. Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of Obesity in Adults: Latest Trends. *Curr Obes Rep* 2018;7:276-88.doi.org/10.1007/s13679-018-0317-8

5. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97. doi.org/10.1001/jama.285.19.2486

6. Wu Q, Xia MF, Gao X. Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus? *World J Diabetes* 2022;13:70-84.doi.org/10.4239/wjd.v13.i2.70

7. Rey-López JP, de Rezende LF, Pastor-Valero M, Tess BH. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. *Obes Rev* 2014;15:781-90.doi.org/10.1111/obr.12198

8. Liu C, Wang C, Guan S, et al. The Prevalence of Metabolically Healthy and Unhealthy Obesity according to Different Criteria. *Obes Facts* 2019;12:78-90.doi.org/10.1159/000495852

9. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. *J Clin Endocrinol Metab* 2006;91:2906-12.doi.org/10.1210/jc.2006-0594

10. Appleton SL, Seaborn CJ, Visvanathan R, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. *Diabetes Care* 2013;36:2388-94.doi.org/10.2337/dc12-1971

11. Feng S, Gong X, Liu H, et al. The Diabetes Risk and Determinants of Transition from Metabolically Healthy to Unhealthy Phenotypes in 49,702 Older Adults: 4-Year Cohort Study. *Obesity (Silver Spring)* 2020;28:1141-8.doi.org/10.1002/oby.22800

12. Wei Y, Wang J, Han X, et al. Metabolically healthy obesity increased diabetes incidence in a middle-aged and elderly Chinese population. *Diabetes Metab Res Rev* 2020;36:e3202.doi.org/10.1002/dmrr.3202

13. Luo D, Liu F, Li X, et al. Comparison of the effect of 'metabolically healthy but obese' and 'metabolically abnormal but not obese' phenotypes on development of diabetes and cardiovascular disease in Chinese. *Endocrine* 2015;49:130-8.doi.org/10.1007/s12020-014-0444-2

14. Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. *Eur Heart J* 2015;36:551-9.doi.org/10.1093/eurheartj/ehu123

15. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. *Obes Rev* 2014;15:504-15.doi.org/10.1111/obr.12157

16. Liu M, Tang R, Wang J, He Y. Distribution of metabolic/obese phenotypes and association with diabetes: 5 years' cohort based on 22,276 elderly. *Endocrine* 2018;62:107-15.doi.org/10.1007/s12020-018-1672-7

- 439 17. Chen Y, Zhang XP, Yuan J, et al. Association of body mass index and age with incident
440 diabetes in Chinese adults: a population-based cohort study. *BMJ Open*
441 2018;8:e021768.doi.org/10.1136/bmjopen-2018-021768
- 442 18. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022.
443 *Diabetes Care* 2022;45:S17-s38.doi.org/10.2337/dc22-S002
- 444 19. Ye J, Guo K, Li X, Yang L, Zhou Z. The Prevalence of Metabolically Unhealthy Normal
445 Weight and Its Influence on the Risk of Diabetes. *J Clin Endocrinol Metab* 2023;108:2240-
446 7.doi.org/10.1210/clinem/dgad152
- 447 20. Wang B, Zhang M, Wang S, et al. Dynamic status of metabolically healthy
448 overweight/obesity and metabolically unhealthy and normal weight and the risk of type 2
449 diabetes mellitus: A cohort study of a rural adult Chinese population. *Obes Res Clin Pract*
450 2018;12:61-71.doi.org/10.1016/j.orcp.2017.10.005
- 451 21. Erviti J, Alonso A, Oliva B, et al. Oral bisphosphonates are associated with increased risk of
452 subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. *BMJ*
453 *Open* 2013;3.doi.org/10.1136/bmjopen-2012-002091
- 454 22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
455 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement:
456 guidelines for reporting observational studies. *Int J Surg.* 2014;12:1495-
457 9.doi.org/10.1016/j.ijsu.2014.07.013
- 458 23. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic
459 syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large
460 cohort studies. *BMC Endocr Disord* 2014;14:9.doi.org/10.1186/1472-6823-14-9
- 461 24. Geetha L, Deepa M, Anjana RM, Mohan V. Prevalence and clinical profile of metabolic
462 obesity and phenotypic obesity in Asian Indians. *J Diabetes Sci Technol* 2011;5:439-
463 46.doi.org/10.1177/193229681100500235
- 464 25. Cherqaoui R, Kassim TA, Kwagyan J, et al. The metabolically healthy but obese phenotype in
465 African Americans. *J Clin Hypertens (Greenwich)* 2012;14:92-6.doi.org/10.1111/j.1751-
466 7176.2011.00565.x
- 467 26. Twig G, Afek A, Derazne E, et al. Diabetes risk among overweight and obese metabolically
468 healthy young adults. *Diabetes Care* 2014;37:2989-95.doi.org/10.2337/dc14-0869
- 469 27. Vaidya A, Cui L, Sun L, et al. A prospective study of impaired fasting glucose and type 2
470 diabetes in China: The Kailuan study. *Medicine (Baltimore)*
471 2016;95:e5350.doi.org/10.1097/md.0000000000005350
- 472 28. Langenberg C, Sharp SJ, Schulze MB, et al. Long-term risk of incident type 2 diabetes and
473 measures of overall and regional obesity: the EPIC-InterAct case-cohort study. *PLoS Med*
474 2012;9:e1001230.doi.org/10.1371/journal.pmed.1001230
- 475 29. Zhu Y, Hu C, Lin L, et al. Obesity mediates the opposite association of education and diabetes
476 in Chinese men and women: Results from the REACTION study. *J Diabetes* 2022;14:739-
477 48.doi.org/10.1111/1753-0407.13325
- 478 30. Bragg F, Tang K, Guo Y, et al. Associations of General and Central Adiposity With Incident
479 Diabetes in Chinese Men and Women. *Diabetes Care.* 2018;41:494-
480 502.doi.org/10.2337/dc17-1852
- 481 31. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk,
482 Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev* 2016;37:278-

1
2
3
4 483
5 484
6 485
7 486
8 487
9 488
10 489
11 490
12 491
13 492
14 493
15 494
16 495
17 496
18 497
19 498
20 499
21 500
22 501
23 502
24 503
25 504
26 505
27 506
28 507
29 508
30 509
31 510
32 511
33 512
34 513
35 514
36 515
37 516
38 517
39 518
40 519
41 520
42 521
43 522
44 523
45 524
46 525
47 526
48
49
50
51
52
53
54
55
56
57
58
59
60

316.doi.org/10.1210/er.2015-1137

32. Logue J, Walker JJ, Colhoun HM, et al. Do men develop type 2 diabetes at lower body mass indices than women? *Diabetologia*. 2011;54:3003-6.doi.org/10.1007/s00125-011-2313-3

33. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. *Diabetes Res Clin Pract*. 2014;105:141-50.doi.org/10.1016/j.diabres.2014.04.006

34. Zhao R, Tang D, Yi S, et al. Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. *PLoS One*. 2014;9:e85770. doi.org/10.1371/journal.pone.0085770

35. Jung CH, Lee MJ, Kang YM, et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. *J Clin Endocrinol Metab*. 2015;100:934-41.doi.org/10.1210/jc.2014-3885

36. Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-Inflammation and Metabolic Reprogramming of Macrophages in Diabetes and Obesity: The Importance of Metabolites. *Front Immunol*. 2021;12:746151.doi.org/10.3389/fimmu.2021.746151

37. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. *Immunity*. 2022;55:31-55.doi.org/10.1016/j.immuni.2021.12.013

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Table 1 The characteristics of the study participants stratified by BMI group.

Variables	Total	MHNW	MHOW	MHO	<i>P</i> -value
N	47391	34920	10932	1539	
Age (years)	40.95 ± 11.05	40.10 ± 10.70	43.38 ± 11.60	42.93 ± 12.07	<0.001
Male, n (%)	22586 (47.66)	14124 (40.45)	7369 (67.41)	1093 (71.02)	<0.001
BMI (kg/m ²)	22.48 ± 2.59	21.25 ± 1.48	25.41 ± 1.05	29.56 ± 1.69	<0.001
FPG (mmol/L)	4.82 ± 0.52	4.78 ± 0.52	4.92 ± 0.52	4.99 ± 0.54	<0.001
SBP (mmHg)	110.88 ± 10.24	109.65 ± 10.30	114.07 ± 9.31	116.26 ± 8.63	<0.001
DBP (mmHg)	69.23 ± 7.47	68.45 ± 7.43	71.22 ± 7.14	72.63 ± 7.13	<0.001
TG (mmol/L)	0.92 ± 0.34	0.87 ± 0.32	1.06 ± 0.33	1.16 ± 0.32	<0.001
TC (mmol/L)	4.69 ± 0.80	4.65 ± 0.80	4.79 ± 0.80	4.84 ± 0.79	<0.001
HDL-C (mmol/L)	1.50 ± 0.26	1.53 ± 0.27	1.42 ± 0.23	1.38 ± 0.21	<0.001
LDL-C (mmol/L)	2.70 ± 0.62	2.66 ± 0.61	2.80 ± 0.62	2.85 ± 0.63	<0.001
ALT (mmol/L)	22.49 ± 10.50	21.66 ± 10.15	24.46 ± 10.94	27.46 ± 11.82	<0.001
AST (mmol/L)	20.22 ± 18.34	18.05 ± 16.65	25.39 ± 20.72	32.80 ± 23.65	<0.001
BUN (mmol/L)	4.63 ± 1.16	4.56 ± 1.14	4.84 ± 1.17	4.91 ± 1.13	<0.001
SCr (mmol/L)	68.87 ± 15.47	67.05 ± 14.79	73.92 ± 16.32	74.36 ± 14.91	<0.001
Smoking status, n (%)					<0.001
Current smoker	2049 (4.32)	1277 (3.66)	667 (6.10)	105 (6.82)	
Ever smoker	493 (1.04)	284 (0.81)	181 (1.66)	28 (1.82)	
Never smoker	10221 (21.57)	7600 (21.76)	2313 (21.16)	308 (20.01)	
Drinking status, n (%)					<0.001
Current drinker	249 (0.53)	144 (0.41)	85 (0.78)	20 (1.30)	
Ever drinker	2117 (4.47)	1274 (3.65)	740 (6.77)	103 (6.69)	
Never drinker	10397 (21.94)	7743 (22.17)	2336 (21.37)	318 (20.66)	
Family history of diabetes, n (%)					0.874
Yes	1061 (2.24)	789 (2.26)	239 (2.19)	33 (2.14)	

Table 2 Relationship between BMI categories and the risk of hyperglycemia among the metabolically healthy participants

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
Hyperglycemia				
BMI	5274/47391	1.14 (1.13, 1.15)	1.10 (1.09, 1.11)	1.06 (1.04, 1.07)
MHNW	3139/34920	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	1798/10932	1.85 (1.75, 1.97)	1.51 (1.42, 1.60)	1.23 (1.16, 1.30)
MHO	337/1539	2.63 (2.35, 2.95)	2.10 (1.88, 2.36)	1.49 (1.33, 1.67)
<i>P</i> for trend		<0.001	<0.001	<0.001

Model I: we adjusted age, gender and the family history of diabetes;
Model II: we further adjusted baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

Table 3 Multivariate-adjusted HR (95% CI) of hyperglycemia among BMI categories in stratified analyses

	MHNW	MHOW	MHO	<i>P</i> interaction
Gender				<0.001
Male	1.00 (Ref.)	1.11 (1.03, 1.20)	1.32 (1.15, 1.51)	
Female	1.00 (Ref.)	1.43 (1.29, 1.58)	1.88 (1.52, 2.32)	
Age (years)				0.534
< 40	1.00 (Ref.)	1.32 (1.17, 1.48)	1.51 (1.21, 1.89)	
≥ 40	1.00 (Ref.)	1.22 (1.13, 1.31)	1.53 (1.34, 1.75)	
Family history of diabetes				0.290
yes	1.00 (Ref.)	1.23 (1.15, 1.30)	1.46 (1.30, 1.65)	
no	1.00 (Ref.)	1.05 (0.71, 1.55)	2.12 (1.07, 4.19)	

Adjusted for maternal gender (except gender subgroup), age (except age subgroup), family history of diabetes (except “family history of diabetes” subgroup), and baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).




Figure 1. Study flow chart

Fig.1 Flowchart of this study.

630x666mm (72 x 72 DPI)




Fig.2 Kaplan-Meier curves for cumulative hazards of hyperglycemia incident risk. Figure showed that the cumulative risk of incident hyperglycemia was markedly different among the BMI categories (log-rank test, $P < 0.001$) and increased gradually with increase of BMI, resulting in maximum risk of prediabetes in the MHO group.

173x128mm (96 x 96 DPI)

Supplementary Table 1

The characteristics of the study participants with/without hyperglycemia

Variables	Non-hyperglycemia	Hyperglycemia	<i>P</i> -value
N	42117	5274	
Age (years)	40.25 ± 10.66	46.54 ± 12.48	<0.001
Male, n (%)	19401 (46.06)	3185 (60.39)	<0.001
BMI (kg/m ²)	22.35 ± 2.53	23.48 ± 2.81	<0.001
FPG (mmol/L)	4.77 ± 0.51	5.20 ± 0.51	<0.001
SBP (mmHg)	110.53 ± 10.26	113.72 ± 9.70	<0.001
DBP (mmHg)	69.01 ± 7.48	70.95 ± 7.21	<0.001
TG (mmol/L)	0.91 ± 0.33	1.01 ± 0.34	<0.001
TC (mmol/L)	4.67 ± 0.80	4.83 ± 0.83	<0.001
HDL-C (mmol/L)	1.51 ± 0.26	1.46 ± 0.25	<0.001
LDL-C (mmol/L)	2.69 ± 0.62	2.79 ± 0.63	<0.001
ALT (mmol/L)	22.35 ± 10.46	23.63 ± 10.71	<0.001
AST (mmol/L)	19.89 ± 18.03	22.92 ± 20.38	<0.001
BUN (mmol/L)	4.60 ± 1.15	4.88 ± 1.18	<0.001
SCr (mmol/L)	68.44 ± 15.46	72.27 ± 15.09	<0.001
Smoking status, n (%)			<0.001
Current smoker	1741 (4.13)	308 (5.84)	
Ever smoker	441 (1.05)	52 (0.99)	
Never smoker	9171 (21.78)	1050 (19.91)	
Drinking status, n (%)			0.003
Current drinker	211 (0.50)	38 (0.72)	
Ever drinker	1844 (4.38)	273 (5.18)	
Never drinker	9298 (22.08)	1099 (20.84)	
Family history of diabetes, n (%)			0.039
Yes	922 (2.19)	139 (2.64)	

Supplementary Table 2
The results of univariate analysis for the risk factors of hyperglycemia

Covariables	HR (95%CI)	P-value
Age (years)	1.04 (1.03, 1.04)	<0.001
Gender		<0.001
Male	Ref.	
Female	0.60 (0.57, 0.64)	
FPG (mmol/L)	5.95 (5.63, 6.28)	<0.001
SBP (mmHg)	1.03 (1.03, 1.03)	<0.001
DBP (mmHg)	1.03 (1.02, 1.03)	<0.001
TG (mmol/L)	2.34 (2.17, 2.53)	<0.001
TC (mmol/L)	1.17 (1.13, 1.20)	<0.001
HDL-C (mmol/L)	0.62 (0.55, 0.68)	<0.001
LDL-C (mmol/L)	1.31 (1.26, 1.37)	<0.001
ALT (mmol/L)	1.00 (1.00, 1.00)	<0.001
AST (mmol/L)	1.01 (1.00, 1.01)	<0.001
BUN (mmol/L)	1.16 (1.14, 1.18)	<0.001
SCr (mmol/L)	1.01 (1.00, 1.01)	<0.001
Smoking status, n (%)		<0.001
Never smoker	Ref.	
Ever smoker	0.93 (0.70, 1.23)	
Current smoker	1.40 (1.23, 1.59)	
Drinking status, n (%)		<0.001
Never drinker	Ref.	
Ever drinker	1.15 (1.01, 1.31)	
Current drinker	1.56 (1.13, 2.15)	
Family history of diabetes		0.500
No	Ref.	
Yes	1.06 (0.90, 1.26)	

Supplementary Table 3


Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Relationship between BMI categories and the risk of diabetes/IFG among the metabolically healthy participants

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
Diabetes				
BMI	239/47391	1.24 (1.20, 1.28)	1.19 (1.14, 1.24)	1.14 (1.09, 1.18)
MHNR	116/34920	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	91/10932	2.53 (1.92, 3.32)	1.78 (1.348, 2.36)	1.39 (1.05, 1.85)
MHO	32/1539	6.84 (4.62, 10.11)	4.55 (3.05, 6.78)	2.91 (1.94, 4.37)
<i>P</i> for trend		<0.001	<0.001	<0.001
IFG				
BMI	5035/47152	1.14 (1.13, 1.15)	1.10 (1.09, 1.11)	1.05 (1.04, 1.07)
MHNR	3023/34804	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	1707/10841	1.85 (1.74, 1.96)	1.51 (1.42, 1.61)	1.23 (1.16, 1.31)
MHO	305/1507	2.54 (2.26, 2.86)	2.07 (1.83, 2.33)	1.49 (1.32, 1.68)
<i>P</i> for trend		<0.001	<0.001	<0.001

Model I: we adjusted age, gender and the family history of diabetes;

Model II: we further adjusted baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.



Supplementary Fig.1 Restricted cubic spline analyses illustrating the dose-response relationship between BMI and the incidence of hyperglycemia.

BMJ Open

Metabolically healthy overweight/obesity with no metabolic abnormalities and incident hyperglycemia in Chinese adults: analysis of a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-087307.R1
Article Type:	Original research
Date Submitted by the Author:	27-Nov-2024
Complete List of Authors:	Gao, Qin; Jining Medical College, Liang, Boya; Binzhou Medical University Li, Hongmin; Jining Medical University Xie, Ruining; Jining Medical University Xu, Yaru; Jining Center for Disease Control and Prevention Tong, Yeqing; Hubei Provincial Center for Disease Control and Prevention Jiang , Shunli; Jining Medical University, ;
Primary Subject Heading:	Public health
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology
Keywords:	Obesity, DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Metabolically healthy overweight/obesity with no metabolic abnormalities and incident hyperglycemia in Chinese adults: analysis of a retrospective cohort study

Qin Gao¹, Boya Liang², Hongmin Li¹, Ruining Xie¹, Yaru Xu³, Yeqing Tong^{4*}, Shunli Jiang^{1*}

* Yeqing Tong and Shunli Jiang contributed equally to this paper.

1 Public Health School, Jining Medical University, Jining, China

2 Public Health School, Binzhou Medical University, Yantai, China

3 Jining Center for Disease Control and Prevention, Jining, China

4 Hubei Provincial Center for Disease Control and Prevention, Wuhan, China

Corresponding Author: Shunli Jiang, 33 Jianshe Road, Rencheng District, Jining, 272000, China. E-mail addresses: utopianjiang@163.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To explore whether metabolically healthy overweight (MHOW) and/or metabolically healthy obesity (MHO) increase hyperglycemia risk in a Chinese population with a board age range.

Design: Retrospective cohort study.

Setting: Secondary analysis of data from the DATADRYAD database, comprising health check records of participants from 32 regions and 11 cities in China between 2010 and 2016.

Participants: A total of 47391 metabolically healthy participants with none of metabolic abnormalities were selected.

Primary and secondary outcome measures: hyperglycemia include incident diabetes and IFG. Diabetes was diagnosed with fasting blood glucose ≥ 7.0 mmol/L and typical clinical symptoms and/or on self-report during follow-up. The FPG level of IFG was from 5.6 to 6.9 mmol/L.

Results: With an average follow-up of 3.06 years, 5274 participants (11.13%) developed hyperglycemia over 144,804 person-years, with an incidence rate of 36.42 per 1000 persons-years. Adjusted model revealed a higher risk of incident hyperglycemia in the MHOW group (HR=1.23, 95%CI: 1.16 to 1.30) and the MHO group (HR=1.49, 95% CI: 1.33 to 1.67) compared with the metabolic healthy normal weight group. With 1 unit increase of BMI, the risk of hyperglycemia increased by 6% (HR = 1.06, 95% CI: 1.04 to 1.07). The stratified analyses and interaction tests showed the robustness of the association, and there were a stronger association in women (*P* for interaction <0.001).

Conclusions: The MHOW and MHO phenotypes were positively associated with higher risk of hyperglycemia in this population. And the association was particularly stronger in women.

Strengths and limitations of this study

1. This retrospective cohort study is representative of the Chinese population, featuring a large sample size and a broad age range.
2. Metabolically healthy status was rigorously defined based on the NCEP ATP-III criteria with none of metabolic abnormalities.
3. Waist circumference was not measured at baseline, limiting the ability to assess the risk of hyperglycemia in individuals with abdominal obesity.
4. Other confounding factors, such as physical activity and dietary factors, were not included in the analysis.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Introduction

Approximately 537 million adults worldwide have been diagnosed with diabetes mellitus, with over 90% being type 2 diabetes mellitus¹. In addition, prediabetes has emerged as a global epidemic. In 2021, 6.2% of the adult population had impaired fasting glucose (IFG), and 10.6% had impaired glucose tolerance¹. Among Chinese adults, the prevalence of diabetes and prediabetes remained high and increased between 2013 and 2018^{2,3}, with an estimated prevalence of 12.4% for diabetes and 38.1% for prediabetes in 2018³.

The global prevalence of obesity has been steadily rising since the early 1980s⁴, which is one of the key risk factors for diabetes mellitus. However, some obese individuals, classified as having metabolically healthy obesity (MHO), do not present with major cardiovascular risk factors. Nonetheless, the MHO phenotype may progress to metabolically unhealthy obesity over time, increasing the risk of cardiovascular disease and mortality.

A critical issue is the inconsistency in defining MHO. The most common definition of MHO is fewer than two of criteria factors of the metabolic syndrome or fewer than one abnormal factor excluding waist circumference (WC)^{5,6}. In 2021, Zembic A et.al have proposed a new definition of MHO based on systolic blood pressure, waist-to-hip ratio and diabetes, and found the cardiovascular mortality risk of the MHO group was not increased when compared the metabolically healthy normal weight (MHNW) individuals⁷. A systematic review reported that the estimated MHO prevalence was about 50% using ≤ 2 metabolic syndrome factors, or 24% using low HOMA-IR, or 13% when defined with no metabolic abnormality⁸. The relationship between MHO and the risk of diabetes remains a topic of interest. Some studies have suggested that MHO individuals are not at increased risk for diabetes compared to their MHNW counterparts^{9, 10}, while others have shown that MHO is indeed associated with a higher risk of diabetes^{11, 12}. Moreover, when MHO is defined strictly with no metabolic abnormalities, the association with diabetes risk appears less significant^{11, 12}. Recent studies have shown that the multi-organ insulin sensitivity in MHO group was lower than the metabolically healthy and lean group¹³. These inconsistent findings may be partly due to the differing age ranges studied, as most previous research focused on middle-aged individuals under 60 years^{9, 10, 14-16}, whereas studies in China predominantly examined older populations^{11, 12, 17}.

Therefore, we aimed to investigate the association between hyperglycemia (including diabetes and IFG) and metabolically healthy individuals without any metabolic abnormalities, based on ATP-III criteria, across young, middle-aged, and elderly groups in a large cohort of the Chinese population.

Methods

Study design and subjects

This study was conducted by the Rich Healthcare Group across 32 sites and 11 cities in China. The subjects who received a health check from 2010 to 2016 were recruited, and the demographic, lifestyle, medical history and family history of chronic disease were collected by questionnaire investigation. As a retrospective cohort study, 685277 participants were selected with at least two visits. After excluding the participant who

1
2
3
4 133 meet the exclusion criteria, a total of 211833 participants (116123 male and 95710
5 134 female) were included (in Figure 1). The information of 211,833 individuals was
6 135 introduced in detail, and the data were download from the “DATADRYAD” database
7 136 (www.datadryad.org) by Chen et al.¹⁸.
8
9 137 For this study, focusing on metabolically healthy status, we excluded participants with
10 138 body mass index (BMI) < 18.5 kg/m² (n = 12,081); systolic blood pressure (SBP) ≥
11 139 130 mmHg and/or diastolic blood pressure (DBP) ≥ 85 mmHg, or missing blood
12 140 pressure values (n = 61,440); fasting plasma glucose (FPG) ≥ 5.6 mmol/L (n = 1,618);
13 141 triglycerides (TG) ≥ 1.7 mmol/L or missing TG values (n = 28,504); or high-density
14 142 lipoprotein cholesterol (HDL-C) ≤ 1.04 mmol/L (men) or ≤ 1.29 mmol/L (women) or
15 143 missing HDL-C values (n = 60,799). A total of 47,391 individuals were included. The
16 144 flowchart is shown in Figure 1.
17
18 145 **Data collection**
19
20 146 As described in the original study, basic information was collected via questionnaire,
21 147 and anthropometric data were measured in a standardized manner. Blood pressure was
22 148 measured using standard mercury sphygmomanometers. Fasting blood samples were
23 149 collected to measure glucose, TG, total cholesterol (TC), low-density lipoprotein
24 150 cholesterol (LDL-C), HDL-C, aspartate transaminase (AST), and alanine
25 151 transaminase (ALT) using an autoanalyzer (Beckman 5800).
26
27 152 **Definitions of obesity, metabolic health**
28
29 153 Body weight was categorized by BMI as follows: normal weight (18.5–23.9 kg/m²),
30 154 overweight (24.0–27.9 kg/m²), and obese (≥ 28.0 kg/m²). WC was not used due to
31 155 collinearity with BMI¹⁵. Metabolic health was defined according to the NCEP ATP-
32 156 III criteria⁵ as the absence of any metabolic abnormalities, which included: SBP ≥
33 157 130 mmHg and/or DBP ≥ 85 mmHg; TG ≥ 1.7 mmol/L; FPG ≥ 5.6 mmol/L; and
34 158 HDL-C ≤ 1.03 mmol/L in men or ≤ 1.29 mmol/L in women.
35
36 159 Based on BMI and metabolic health status, participants were classified into three
37 160 phenotypes: (1) MHNW, (2) metabolically healthy overweight (MHOW), and (3)
38 161 MHO.
39
40 162 **Outcome Measures**
41
42 163 The primary of outcome was hyperglycemia, defined as a dichotomous variable (0 =
43 164 non-hyperglycemia, 1 = hyperglycemia). In this study, hyperglycemia include
44 165 incident diabetes and IFG. Diabetes was diagnosed with fasting blood glucose ≥7.0
45 166 mmol/L and typical clinical symptoms and/or self-report diabetes mellitus during
46 167 follow-up. The FPG level of IFG was from 5.6 to 6.9 mmol/l based on the American
47 168 Diabetes Association criteria¹⁹.
48
49 169 **Covariates**
50
51 170 Covariates were selected based on previous literature^{11, 12, 17, 18, 20, 21}, and included
52 171 continuous variables (age, ALT, AST, LDL-C, TC, blood urea nitrogen [BUN], and
53 172 serum creatinine [SCr]) and categorical variables (gender, smoking status, drinking
54 173 status, and family history of diabetes).
55
56 174 **Missing Data Processing**
57
58 175 Missing data were as follows: LDL-C: 26 (0.05%), ALT: 35 (0.07%), AST: 27433
59 176 (57.89%), BUN: 354 (0.75%), SCr: 113 (0.24%), drinking status: 34628 (73.07%),

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

and smoking status: 34628 (73.07%), respectively. Multiple imputation was applied for missing continuous variables using a chained equation algorithm with the R's MI package. Missing categorical variables were treated as categorical in the analysis ²².

Statistical Analysis

Basic characteristics were presented as mean \pm SD or percentage. Group comparisons were conducted using one-way ANOVA or the Kruskal–Wallis test for continuous variables, and the χ^2 test for categorical variables. The Kaplan–Meier survival method and Cox-proportional hazard model were used to estimate the association of MHOW and MHO for incident hyperglycemia. According to the STROBE statement recommendation ²³, the crude, minor- and full adjustment models were presented. In addition, a restricted cubic spline model was also constructed to assess the dose-response relationship between BMI and hyperglycemia risk.

Subgroup analyses were performed to assess the modifying effects of age, gender, height, and family history of diabetes on the association between BMI and hyperglycemia. Interaction tests were conducted between BMI categories and these subgroup variables. Sensitivity analyses were carried out to assess the robustness of the findings: 1) we did similar analysis after considering diabetes and IFG as separate outcomes; 2) we excluded the participants with missing smoking and drinking status; 3) we excluded the participants with missing AST.

All analyses were conducted using R software (version 4.3.3) and Empower Stats (version 4.1). A two-sided P-value < 0.05 was considered statistically significant.

Patient and public involvement

None.

Results

Basic characteristics of the study participants

A total of 47391 metabolically healthy participants (47.66% male) were finally included. The mean age and BMI were 40.95 ± 11.05 years and 22.48 ± 2.59 kg/m², respectively. During a follow-up period of 3.06 ± 0.95 years, 5,274 participants (11.13%) developed hyperglycemia. The characteristics stratified by BMI categories and the status of blood glucose are presented in Table 1 and Table S1. Participants with higher BMI generally had higher FPG, SBP, DBP, TG, TC, LDL-C, ALT, AST, BUN, and SCr levels, lower HDL-C level, and had a higher proportion of males, current smokers, and current drinkers ($P < 0.001$; Table 1). During follow-up, all characteristics of hyperglycemic participants were different from those of participants without hyperglycemia ($P < 0.05$; Table S1).

Univariate analysis for hyperglycemia in the metabolically healthy population

Table S2 showed that higher age, BMI, FPG, DBP, SBP, TG, TC, LDL, AST, and ALT levels, current drinkers and smokers, and lower HDL-C level were the risk factors of hyperglycemia. Females had a lower risk of hyperglycemia than males. In Figure 2, the Kaplan–Meier curve showed that higher hazards were determined among MHOW and MHO (log-rank test, $P < 0.001$).

Association of MHOW/MHO and hyperglycemia risk among metabolically healthy participants

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In metabolically healthy participants, 5,274 individuals developed hyperglycemia over 144,804 person-years of follow-up, and the overall rate of hyperglycemia was 36.42 per 1000 person-years. The rate of hyperglycemia was 29.35 in MHNW group, 54.07 in MHOW group, and 72.24 in MHO group per 1000 person-years, respectively.

The hazard ratio (HR) and 95% confidence intervals (CI) of the BMI categories on the incidence of hyperglycemia are listed in Table 2. In the crude model, compared with MHNW participants, the risk of hyperglycemia increased 85% in the MHOW group (HR = 1.85, 95% CI:1.75 to 1.97), and 163% in the MHO group (HR = 2.63, 95% CI:2.35 to 2.95), respectively. After adjusting for age, gender, and family history of diabetes, the risk of hyperglycemia in MHOW group and MHO group was still higher than in MHNW group. Furthermore, after adjusting for all the covariates, the relationship was not completely eliminated, with HRs (95% CI) of 1.23 (1.16–1.30) for MHOW and 1.49 (1.33–1.67) for MHO (*P* for trend < 0.001). Moreover, we analyzed the correlation between BMI as a continuous variable and the hyperglycemia risk. The risk of incident of hyperglycemia increased by 6% (HR = 1.06, 95% CI:1.04 to 1.07, *P* < 0.001) with 1 unit increase of BMI.

The restricted cubic spline model showed the risk of hyperglycemia increased gradually with increase in BMI, albeit in a nonlinear manner (*P* < 0.001, *P*-nonlinearity = 0.039, Figure S1).

Subgroup analyses and sensitivity analyses

The results of the stratified analyses and interaction effects are presented in Table 3. The additive interactions between MHOW/MHO and hyperglycemia risk were observed in gender, and stronger correlation was found in female participants. However, no significant interaction was found in age, height or family history of diabetes.

In addition, sensitivity analyses were performed for the risk of diabetes and IFG to confirm the robustness of our results (Table S3). After adjusting for covariates, the HR (95% CI) of incident diabetes was 1.39 (1.05-1.85) for MHOW and 2.91 (1.94-4.37) for MHO (*P* for trend <0.001); the HR (95% CI) of IFG was 1.23 (1.16-1.31) for MHOW and 1.49 (1.32-1.68) for MHO (*P* for trend <0.001). Furthermore, to verify the association of MHOW/MHO and hyperglycemia, the sensitivity analyses were performed as excluding the individuals with missing data of smoking and drinking status (n=12763, Table S4) or AST (n=19955, Table S5). The positive relationship of MHOW/MHO and hyperglycemia risk was still significant.

Discussion

The association between the BMI categories and incident hyperglycemia in the metabolically healthy population was examined in this cohort study. Compared to the MHNW group, both the MHOW and MHO groups exhibited a progressive increase in the risk of hyperglycemia, revealing a clear trend of rising hyperglycemia incidence with higher BMI. This present study suggests that the presence of MHOW/MHO, even with the absence of metabolic risk factors, significantly elevates the incidence of hyperglycemia. Consequently, MHOW and/or MHO should not be treated as a healthy status. Notably, weight management may serve as an effective strategy for preventing hyperglycemia and its related metabolic diseases among individuals with

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

MHOW or MHO.

The BioSHaRE-EU Healthy Obese Project have shown that the MHO prevalence of was 7%-28% for women, and 2%-19% for men²⁴. The MHO prevalence ranged from 4.2% in a Chinese cohort⁸ to 13.3% among Asian Indians²⁵ and 28.5% in African Americans²⁶. In this study, the prevalence of MHOW (21.93%) and MHO (3.25%) were lower than previous reports, likely due to the strict definition of metabolically healthy status with none of metabolic abnormalities.

Wu et al. highlighted the positive effect of MHO on diabetes based on large numbers of epidemiological studies worldwide⁶. However, the correlation weakens when metabolically healthy status is strictly defined with none of metabolic abnormalities. Notably, the incidence of diabetes increased by 35-67% with one metabolic abnormality addition among metabolic healthy participants²⁷. For example, Feng et al. found that the risk of diabetes increased among MHO individuals in a cohort of 49,702 older adults, but the association was not statistically significant when MHO was defined without ATP-III risk factors¹¹. Similarly, Wei et al. observed an increased diabetes risk among MHO individuals, but this was not statistically significant among those with no metabolic abnormalities in the Dongfeng Tongji cohort study¹².

Despite these findings, our study identified a higher risk of hyperglycemia in the MHOW and MHO groups, even with the strict definition of metabolically healthy status as the absence of any metabolic abnormalities. Additionally, we found the positive association of MHOW/MHO phenotype on diabetes and IFG, respectively. In consistent, the risk of diabetes for MHOW or MHO individuals with no metabolic abnormalities was 1.89 and 3.88 times higher, respectively, than in MHNW young men²⁷. These inconsistent results may be attributed to several factors. First, age differences may partly explain the variability in findings. The participants in previous studies had mean ages of 63.2 years¹¹ and 66 (63–71) years¹², whereas the mean age in our study was 40.95 ± 11.05 years. Younger MHO adults may present a higher hyperglycemia risk, as they are more likely to develop metabolic abnormalities in the short term. In contrast, middle-aged MHO individuals may have been overweight or obese for years without developing diabetes or metabolic disorders. Moreover, the concept of “metabolically healthy” status tends to diminish with aging²⁴, which likely accounts for the reduced prevalence of MHOW and MHO in earlier studies^{11,12}.

Notably, the interaction between gender and BMI categories on incident hyperglycemia was significant, with a higher risk observed in women than in men. This finding aligns with some studies^{28,29}, but not all^{30,31}. For example, one cohort study found that the risk of diabetes and IFG was higher in obese women²⁸. Similarly, another prospective case-cohort study noted a strong association between WC and type 2 diabetes mellitus, particularly in women²⁹. However, the China Kadoorie Biobank study found greater hazard ratios for diabetes associated with BMI increments in men than in women (P for heterogeneity < 0.001)³¹. Previous studies have indicated that obesity is a more common and stronger risk factor for diabetes in women^{32,33}.

The mechanism of positive association between BMI and hyperglycemia incidence in metabolic healthy population still remains unclear. However, it may be partly attributed to increased inflammation and insulin resistance associated with MHOW and/or MHO phenotypes. Overweight and obesity are known to induce chronic low-grade inflammation, particularly in insulin-sensitive tissues such as the liver, muscle, and adipose tissues³⁴. Evidence suggests that chronic inflammation plays a critical role in diabetes development, even among MHO subjects^{35, 36}. The accumulation and infiltration of pro-inflammatory macrophages in adipose tissue are significant contributors to chronic inflammation³⁷. Pro-inflammatory cytokines, mainly secreted by macrophages, such as tumor necrosis factor (TNF- α) and interleukin-1 beta (IL-1 β), can trigger various signaling pathways that induce insulin resistance. Key signaling pathways include TNF- α /IKK β /NF- κ B and TLR4/NLRP3/caspase-1/IL-1 β , which impair insulin action and modulate pancreatic β -cell mass and function³⁸. In addition, the prevalence of non-alcoholic fatty liver disease (NAFLD) is continually increasing due to the obesity epidemic³⁹. NAFLD is not a consequence of insulin resistance, but it is also a key cause of insulin resistance or diabetes mellitus⁴⁰. The high prevalence of NAFLD and visceral adiposity was found among the MHOW/MHO group, compared with the MHNW group⁴¹. In a MR analysis of data from the UK Biobank, the positive relationship of higher liver fat content and the risk of type 2 diabetes was observed⁴². Previous have shown that the increased hepatic lipogenesis and lipodystrophy-like phenotypes with visceral adiposity, resulted in dysregulated hepatokines and dysregulated adipokines, which might be the main cause of insulin resistance⁴⁰. However, Wei et.al¹² found the association of the MHO phenotype and increased diabetes incidence did not differ by the presence or absence of NAFLD.

Study strengths and limitations

In addition to its large sample size and broad age range, this study has several strengths. Metabolically healthy individuals were included without any metabolic risk factors, allowing for the independent assessment of the role of BMI in hyperglycemia risk. Furthermore, sensitivity analyses, subgroup analyses, and interaction effects were examined to validate the reliability and stability of the results. However, there are several limitations to our study. First, WC was not measured at baseline, which prevented us from combining WC and BMI to distinguish individuals with abdominal obesity or predict the risk of hyperglycemia among those with abdominal obesity. Second, hyperglycemia prevalence may be underestimated, as random plasma glucose and/or postprandial plasma glucose levels were not collected. Finally, although numerous confounding factors were included, some potential factors may still be unaccounted for, such as physical activity, blood pressure-and lipids-lowering medicines and dietary habits.

Conclusion

In conclusion, this study demonstrated that MHOW and MHO are independently and positively associated with the risk of incident hyperglycemia in metabolically healthy adults, with a particularly strong correlation observed in women. Given the unsteady characteristics of metabolically healthy obese phenotypes, these findings underscore

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

the necessity of weight loss, increasing physical activity and diet quality management to reduce hyperglycemia risk and promote overall population health.

Acknowledgments

We thank the field investigators and participants of the Rich Healthcare Group as well as Chen et al. for sharing their database. We thank LetPub (www.letpub.com.cn) for its linguistic assistance during the preparation of this manuscript.

Footnotes

Contributions

QG, QTY and SLJ: study design. QG, BYL, HML, RNX and YRX: data cleaning and analysis. QG, BYL, HML, RNX and YRX: result interpretation. QG: manuscript writing. BYL and HML: manuscript editing. All authors approved the final manuscript. Guarantor is QG.

Funding

This work was supported by the National Natural Science Foundation of China (82204031), Natural Science Foundation of Shandong Province (ZR2021QH188), and the Lin He's Academician Workstation of New Medicine and Clinical Translation in Jining Medical University (JYHL2022MS13).

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data availability statement

The data used in this analysis can be accessed via the Dryad data repository at <http://datadryad.org/withthedoi:10.5061/dryad.ft8750v>.

Ethics statements

Patient consent: Not required.

Ethics approval: This study was approved by the Rich Healthcare Group Review Board, and the information was retrieved retrospectively.

References

1. International Diabetes Federation. IDF Diabetes Atlas 10th Edition [M]. 2021.

2. Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. *JAMA* 2017;317:2515-23.doi.org/10.1001/jama.2017.7596

3. Wang L, Peng W, Zhao Z, et al. Prevalence and Treatment of Diabetes in China, 2013-2018. *JAMA* 2021;326:2498-506.doi.org/10.1001/jama.2021.22208

4. Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of Obesity in Adults: Latest Trends. *Curr Obes Rep* 2018;7:276-88.doi.org/10.1007/s13679-018-0317-8

5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143-421.

6. Wu Q, Xia MF, Gao X. Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus? *World J Diabetes* 2022;13:70-84.doi.org/10.4239/wjd.v13.i2.70

7. Zembic A, Eckel N, Stefan N, et.al. An Empirically Derived Definition of Metabolically Healthy Obesity Based on Risk of Cardiovascular and Total Mortality. *JAMA Netw Open*. 2021;4(5):e218505. doi:10.1001/jamanetworkopen.2021.8505

8. Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. *J Clin Invest*. 2019;129(10):3978-89. doi: 10.1172/JCI129186.

9. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. *J Clin Endocrinol Metab* 2006;91:2906-12.doi.org/10.1210/jc.2006-0594

10. Appleton SL, Seaborn CJ, Visvanathan R, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. *Diabetes Care* 2013;36:2388-94.doi.org/10.2337/dc12-1971

11. Feng S, Gong X, Liu H, et al. The Diabetes Risk and Determinants of Transition from Metabolically Healthy to Unhealthy Phenotypes in 49,702 Older Adults: 4-Year Cohort Study. *Obesity (Silver Spring)* 2020;28:1141-8.doi.org/10.1002/oby.22800

12. Wei Y, Wang J, Han X, et al. Metabolically healthy obesity increased diabetes incidence in a middle-aged and elderly Chinese population. *Diabetes Metab Res Rev* 2020;36:e3202.doi.org/10.1002/dmrr.3202

13. Petersen MC, Smith GI, Palacios HH, et al. Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity. *Cell Metab*. 2024;36(4):745-61.e5. doi:10.1016/j.cmet.2024.03.002

14. Luo D, Liu F, Li X, et al. Comparison of the effect of 'metabolically healthy but obese' and 'metabolically abnormal but not obese' phenotypes on development of diabetes and cardiovascular disease in Chinese. *Endocrine* 2015;49:130-8.doi.org/10.1007/s12020-014-0444-2

15. Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. *Eur Heart J*

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

- 2015;36:551-9.doi.org/10.1093/eurheartj/ehu123
16. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. *Obes Rev* 2014;15:504-15.doi.org/10.1111/obr.12157
 17. Liu M, Tang R, Wang J, He Y. Distribution of metabolic/obese phenotypes and association with diabetes: 5 years' cohort based on 22,276 elderly. *Endocrine* 2018;62:107-15.doi.org/10.1007/s12020-018-1672-7
 18. Chen Y, Zhang XP, Yuan J, et al. Association of body mass index and age with incident diabetes in Chinese adults: a population-based cohort study. *BMJ Open* 2018;8:e021768.doi.org/10.1136/bmjopen-2018-021768
 19. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. *Diabetes Care* 2022;45:S17-s38.doi.org/10.2337/dc22-S002
 20. Ye J, Guo K, Li X, Yang L, Zhou Z. The Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. *J Clin Endocrinol Metab* 2023;108:2240-7.doi.org/10.1210/clinem/dgad152
 21. Wang B, Zhang M, Wang S, et al. Dynamic status of metabolically healthy overweight/obesity and metabolically unhealthy and normal weight and the risk of type 2 diabetes mellitus: A cohort study of a rural adult Chinese population. *Obes Res Clin Pract* 2018;12:61-71.doi.org/10.1016/j.orcp.2017.10.005
 22. Erviti J, Alonso A, Oliva B, et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. *BMJ Open* 2013;3.doi.org/10.1136/bmjopen-2012-002091
 23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg.* 2014;12:1495-9.doi.org/10.1016/j.ijsu.2014.07.013
 24. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. *BMC Endocr Disord* 2014;14:9.doi.org/10.1186/1472-6823-14-9
 25. Geetha L, Deepa M, Anjana RM, Mohan V. Prevalence and clinical profile of metabolic obesity and phenotypic obesity in Asian Indians. *J Diabetes Sci Technol* 2011;5:439-46.doi.org/10.1177/193229681100500235
 26. Cherqaoui R, Kassim TA, Kwagyan J, et al. The metabolically healthy but obese phenotype in African Americans. *J Clin Hypertens (Greenwich)* 2012;14:92-6.doi.org/10.1111/j.1751-7176.2011.00565.x
 27. Twig G, Afek A, Derazne E, et al. Diabetes risk among overweight and obese metabolically healthy young adults. *Diabetes Care* 2014;37:2989-95.doi.org/10.2337/dc14-0869
 28. Vaidya A, Cui L, Sun L, et al. A prospective study of impaired fasting glucose and type 2 diabetes in China: The Kailuan study. *Medicine (Baltimore)* 2016;95:e5350.doi.org/10.1097/md.0000000000005350
 29. Langenberg C, Sharp SJ, Schulze MB, et al. Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. *PLoS Med* 2012;9:e1001230.doi.org/10.1371/journal.pmed.1001230
 30. Zhu Y, Hu C, Lin L, et al. Obesity mediates the opposite association of education and diabetes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

in Chinese men and women: Results from the REACTION study. *J Diabetes* 2022;14:739-48.doi.org/10.1111/1753-0407.13325

31. Bragg F, Tang K, Guo Y, et al. Associations of General and Central Adiposity With Incident Diabetes in Chinese Men and Women. *Diabetes Care*. 2018;41:494-502.doi.org/10.2337/dc17-1852

32. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev* 2016;37:278-316.doi.org/10.1210/er.2015-1137

33. Logue J, Walker JJ, Colhoun HM, et al. Do men develop type 2 diabetes at lower body mass indices than women? *Diabetologia*. 2011;54:3003-6.doi.org/10.1007/s00125-011-2313-3

34. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. *Diabetes Res Clin Pract*. 2014;105:141-50.doi.org/10.1016/j.diabres.2014.04.006

35. Zhao R, Tang D, Yi S, et al. Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. *PLoS One*. 2014;9:e85770. doi.org/10.1371/journal.pone.0085770

36. Jung CH, Lee MJ, Kang YM, et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. *J Clin Endocrinol Metab*. 2015;100:934-41.doi.org/10.1210/jc.2014-3885

37. Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-Inflammation and Metabolic Reprogramming of Macrophages in Diabetes and Obesity: The Importance of Metabolites. *Front Immunol*. 2021;12:746151.doi.org/10.3389/fimmu.2021.746151

38. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. *Immunity*. 2022;55:31-55.doi.org/10.1016/j.immuni.2021.12.013

39. European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol*. 2024;81(3):492-542. [doi:10.1016/j.jhep.2024.04.031](https://doi.org/10.1016/j.jhep.2024.04.031)

40. Stefan N, Schick F, Birkenfeld AL, Häring HU, White MF. The role of hepatokines in NAFLD. *Cell Metab*. 2023;35(2):236-52. [doi:10.1016/j.cmet.2023.01.006](https://doi.org/10.1016/j.cmet.2023.01.006)

41. Stefan N, Schick F, Häring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. *Cell Metab*. 2017;26(2):292-300. [doi:10.1016/j.cmet.2017.07.008](https://doi.org/10.1016/j.cmet.2017.07.008)

42. Martin S, Sorokin EP, Thomas EL, et al. Estimating the Effect of Liver and Pancreas Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study. *Diabetes Care*. 2022;45(2):460-8. [doi:10.2337/dc21-1262](https://doi.org/10.2337/dc21-1262)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

528

529

Table 1 Characteristics of study participants stratified by BMI group.

Variables	Total	MHNW	MHOW	MHO	P-value
N	47391	34920	10932	1539	
Age (years)	40.95 ± 11.05	40.10 ± 10.70	43.38 ± 11.60	42.93 ± 12.07	<0.001
Male, n (%)	22586 (47.66)	14124 (40.45)	7369 (67.41)	1093 (71.02)	<0.001
BMI (kg/m ²)	22.48 ± 2.59	21.25 ± 1.48	25.41 ± 1.05	29.56 ± 1.69	<0.001
FPG (mmol/L)	4.82 ± 0.52	4.78 ± 0.52	4.92 ± 0.52	4.99 ± 0.54	<0.001
SBP (mmHg)	110.88 ± 10.24	109.65 ± 10.30	114.07 ± 9.31	116.26 ± 8.63	<0.001
DBP (mmHg)	69.23 ± 7.47	68.45 ± 7.43	71.22 ± 7.14	72.63 ± 7.13	<0.001
TG (mmol/L)	0.92 ± 0.34	0.87 ± 0.32	1.06 ± 0.33	1.16 ± 0.32	<0.001
TC (mmol/L)	4.69 ± 0.80	4.65 ± 0.80	4.79 ± 0.80	4.84 ± 0.79	<0.001
HDL-C (mmol/L)	1.50 ± 0.26	1.53 ± 0.27	1.42 ± 0.23	1.38 ± 0.21	<0.001
LDL-C (mmol/L)	2.70 ± 0.62	2.66 ± 0.61	2.80 ± 0.62	2.85 ± 0.63	<0.001
ALT (mmol/L)	22.49 ± 10.50	21.66 ± 10.15	24.46 ± 10.94	27.46 ± 11.82	<0.001
AST (mmol/L)	20.22 ± 18.34	18.05 ± 16.65	25.39 ± 20.72	32.80 ± 23.65	<0.001
BUN (mmol/L)	4.63 ± 1.16	4.56 ± 1.14	4.84 ± 1.17	4.91 ± 1.13	<0.001
SCr (mmol/L)	68.87 ± 15.47	67.05 ± 14.79	73.92 ± 16.32	74.36 ± 14.91	<0.001
Smoking status, n (%)					<0.001
Current smoker	2049 (4.32)	1277 (3.66)	667 (6.10)	105 (6.82)	
Ever smoker	493 (1.04)	284 (0.81)	181 (1.66)	28 (1.82)	
Never smoker	10221 (21.57)	7600 (21.76)	2313 (21.16)	308 (20.01)	
Drinking status, n (%)					<0.001
Current drinker	249 (0.53)	144 (0.41)	85 (0.78)	20 (1.30)	
Ever drinker	2117 (4.47)	1274 (3.65)	740 (6.77)	103 (6.69)	
Never drinker	10397 (21.94)	7743 (22.17)	2336 (21.37)	318 (20.66)	
Family history of diabetes, n (%)					0.874
Yes	1061 (2.24)	789 (2.26)	239 (2.19)	33 (2.14)	

Table 2 Relationship between BMI categories and risk of hyperglycemia among metabolically healthy participants

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
Hyperglycemia				
BMI	5274/47391	1.14 (1.13, 1.15)	1.10 (1.09, 1.11)	1.06 (1.04, 1.07)
MHNW	3139/34920	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	1798/10932	1.85 (1.75, 1.97)	1.51 (1.42, 1.60)	1.23 (1.16, 1.30)
MHO	337/1539	2.63 (2.35, 2.95)	2.10 (1.88, 2.36)	1.49 (1.33, 1.67)
P for trend		<0.001	<0.001	<0.001

Model I: adjusted for age, gender and family history of diabetes;
Model II: further adjusted for baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

Table 3 Multivariate-adjusted HR (95% CI) of hyperglycemia among BMI categories in stratified analyses

	MHNW	MHOW	MHO	P interaction
Gender				<0.001
Male	1.00 (Ref.)	1.11 (1.03, 1.20)	1.32 (1.15, 1.51)	
Female	1.00 (Ref.)	1.43 (1.29, 1.58)	1.88 (1.52, 2.32)	
Age (years)				0.534
< 40	1.00 (Ref.)	1.32 (1.17, 1.48)	1.51 (1.21, 1.89)	
≥ 40	1.00 (Ref.)	1.22(1.13, 1.31)	1.53 (1.34, 1.75)	
Family history of diabetes				0.290
yes	1.00 (Ref.)	1.23 (1.15, 1.30)	1.46 (1.30, 1.65)	
no	1.00 (Ref.)	1.05 (0.71, 1.55)	2.12 (1.07, 4.19)	
Height (cm)		1.31 (1.16, 1.47)	1.75 (1.38, 2.21)	0.056
≤ 161.90	1.00 (Ref.)	1.31 (1.16, 1.47)	1.75 (1.38, 2.21)	
162.00-169.90	1.00 (Ref.)	1.26 (1.13, 1.40)	1.33 (1.07, 1.64)	
≥ 170.00	1.00 (Ref.)	1.15 (1.04, 1.26)	1.50 (1.26, 1.78)	

Adjusted for gender (except gender subgroup), age (except age subgroup), family history of diabetes (except “family history of diabetes” subgroup), and baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

Figure legends:

Figure 1. Study flow chart.

Figure 2. Kaplan–Meier curves for cumulative hazard ratios of incident risk of hyperglycemia. The figure shows that the cumulative risk of incident hyperglycemia was markedly different among the BMI categories (log-rank test, $P < 0.001$) and increased gradually with increasing BMI, resulting in maximum risk of prediabetes in the MHO group.

Figure S1. Restricted cubic spline analyses illustrating the dose-response relationship between BMI and incidence of hyperglycemia.




Figure 1. Study flow chart.

90x90mm (300 x 300 DPI)




Figure 2. Kaplan–Meier curves for cumulative hazard ratios of incident risk of hyperglycemia. The figure shows that the cumulative risk of incident hyperglycemia was markedly different among the BMI categories (log-rank test, $P < 0.001$) and increased gradually with increasing BMI, resulting in maximum risk of prediabetes in the MHO group.

90x90mm (300 x 300 DPI)

Table S1
The characteristics of the study participants with/without hyperglycemia

Variables	Non-hyperglycemia	Hyperglycemia	P-value
N	42117	5274	
Age (years)	40.25 ± 10.66	46.54 ± 12.48	<0.001
Male, n (%)	19401 (46.06)	3185 (60.39)	<0.001
BMI (kg/m ²)	22.35 ± 2.53	23.48 ± 2.81	<0.001
FPG (mmol/L)	4.77 ± 0.51	5.20 ± 0.51	<0.001
SBP (mmHg)	110.53 ± 10.26	113.72 ± 9.70	<0.001
DBP (mmHg)	69.01 ± 7.48	70.95 ± 7.21	<0.001
TG (mmol/L)	0.91 ± 0.33	1.01 ± 0.34	<0.001
TC (mmol/L)	4.67 ± 0.80	4.83 ± 0.83	<0.001
HDL-C (mmol/L)	1.51 ± 0.26	1.46 ± 0.25	<0.001
LDL-C (mmol/L)	2.69 ± 0.62	2.79 ± 0.63	<0.001
ALT (mmol/L)	22.35 ± 10.46	23.63 ± 10.71	<0.001
AST (mmol/L)	19.89 ± 18.03	22.92 ± 20.38	<0.001
BUN (mmol/L)	4.60 ± 1.15	4.88 ± 1.18	<0.001
SCr (mmol/L)	68.44 ± 15.46	72.27 ± 15.09	<0.001
Smoking status, n (%)			<0.001
Current smoker	1741 (4.13)	308 (5.84)	
Ever smoker	441 (1.05)	52 (0.99)	
Never smoker	9171 (21.78)	1050 (19.91)	
Drinking status, n (%)			0.003
Current drinker	211 (0.50)	38 (0.72)	
Ever drinker	1844 (4.38)	273 (5.18)	
Never drinker	9298 (22.08)	1099 (20.84)	
Family history of diabetes, n (%)			0.039
Yes	922 (2.19)	139 (2.64)	

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Table S 2

The results of univariate analysis for the risk factors of hyperglycemia

Covariables	HR (95%CI)	P-value
Age (years)	1.04 (1.03, 1.04)	<0.001
Gender		<0.001
Male	Ref.	
Female	0.60 (0.57, 0.64)	
FPG (mmol/L)	5.95 (5.63, 6.28)	<0.001
SBP (mmHg)	1.03 (1.03, 1.03)	<0.001
DBP (mmHg)	1.03 (1.02, 1.03)	<0.001
TG (mmol/L)	2.34 (2.17, 2.53)	<0.001
TC (mmol/L)	1.17 (1.13, 1.20)	<0.001
HDL-C (mmol/L)	0.62 (0.55, 0.68)	<0.001
LDL-C (mmol/L)	1.31 (1.26, 1.37)	<0.001
ALT (mmol/L)	1.00 (1.00, 1.00)	<0.001
AST (mmol/L)	1.01 (1.00, 1.01)	<0.001
BUN (mmol/L)	1.16 (1.14, 1.18)	<0.001
SCr (mmol/L)	1.01 (1.00, 1.01)	<0.001
Smoking status, n (%)		<0.001
Never smoker	Ref.	
Ever smoker	0.93 (0.70, 1.23)	
Current smoker	1.40 (1.23, 1.59)	
Drinking status, n (%)		<0.001
Never drinker	Ref.	
Ever drinker	1.15 (1.01, 1.31)	
Current drinker	1.56 (1.13, 2.15)	
Family history of diabetes		0.500
No	Ref.	
Yes	1.06 (0.90, 1.26)	

Table S3
Relationship between BMI categories and the risk of diabetes/IFG among the metabolically healthy participants

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
Diabetes				
BMI	239/47391	1.24 (1.20, 1.28)	1.19 (1.14, 1.24)	1.14 (1.09, 1.18)
MHNW	116/34920	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	91/10932	2.53 (1.92, 3.32)	1.78 (1.35, 2.36)	1.39 (1.05, 1.85)
MHO	32/1539	6.84 (4.62, 10.11)	4.55 (3.05, 6.78)	2.91 (1.94, 4.37)
<i>P</i> for trend		<0.001	<0.001	<0.001
IFG				
BMI	5035/47152	1.14 (1.13, 1.15)	1.10 (1.09, 1.11)	1.05 (1.04, 1.07)
MHNW	3023/34804	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	1707/10841	1.85 (1.74, 1.96)	1.51 (1.42, 1.61)	1.23 (1.16, 1.31)

MHO	305/1507	2.54 (2.26, 2.86)	2.07 (1.83, 2.33)	1.49 (1.32,1.68)
<i>P</i> for trend		<0.001	<0.001	<0.001

Model I: adjusted age, gender and the family history of diabetes;

Model II: further adjusted baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

For peer review only

Table S4
Relationship between BMI categories and the risk of hyperglycemia among the metabolically healthy participants without missing data of smoking and drinking status

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
BMI	1410/12763	1.12 (1.10, 1.14)	1.09 (1.07, 1.11)	1.05 (1.03, 1.07)
MHNW	844/9161	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	485/3161	1.73 (1.55, 1.94)	1.43 (1.27, 1.60)	1.16 (1.03, 1.30)
MHO	81/441	2.14 (1.70, 2.69)	1.75 (1.39, 2.21)	1.28 (1.01, 1.61)
P for trend		<0.001	<0.001	<0.001

Model I: adjusted age, gender and the family history of diabetes;
Model II: further adjusted baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

Table S5
Relationship between BMI categories and the risk of hyperglycemia among the metabolically healthy participants without missing data of AST

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
BMI	2717/19955	1.14 (1.12, 1.15)	1.11 (1.09, 1.12)	1.05 (1.04, 1.07)
MHNW	1604/14558	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	945/4742	1.85 (1.70, 2.01)	1.54 (1.42, 1.67)	1.23 (1.13, 1.34)
MHO	168/655	2.51 (2.15, 2.95)	2.06 (1.75, 2.46)	1.49 (1.27, 1.76)
P for trend		<0.001	<0.001	<0.001

Model I: adjusted for age, gender and family history of diabetes;

Model II: further adjusted for baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

For peer review only




Figure S1. Restricted cubic spline analyses illustrating the dose-response relationship between BMI and incidence of hyperglycemia.

90x90mm (300 x 300 DPI)

BMJ Open

Metabolically healthy overweight/obesity with no metabolic abnormalities and incident hyperglycemia in Chinese adults: analysis of a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-087307.R2
Article Type:	Original research
Date Submitted by the Author:	13-Dec-2024
Complete List of Authors:	Gao, Qin; Jining Medical College, Liang, Boya; Binzhou Medical University Li, Hongmin; Jining Medical University Xie, Ruining; Jining Medical University Xu, Yaru; Jining Center for Disease Control and Prevention Tong, Yeqing; Hubei Provincial Center for Disease Control and Prevention Jiang , Shunli; Jining Medical University, ;
Primary Subject Heading:	Public health
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology
Keywords:	Obesity, DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Metabolically healthy overweight/obesity with no metabolic abnormalities and incident hyperglycemia in Chinese adults: analysis of a retrospective cohort study

Qin Gao¹, Boya Liang², Hongmin Li¹, Ruining Xie¹, Yaru Xu³, Yeqing Tong^{4*}, Shunli Jiang^{1*}

1 Public Health School, Jining Medical University, Jining, China

2 Public Health School, Binzhou Medical University, Yantai, China

3 Jining Center for Disease Control and Prevention, Jining, China

4 Hubei Provincial Center for Disease Control and Prevention, Wuhan, China

* Yeqing Tong and Shunli Jiang contributed equally to this paper.

Correspondence to:

Shunli Jiang, 33 Jianshe Road, Rencheng District, Jining, 272000, China

E-mail addresses: utopianjiang@163.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: To explore whether metabolically healthy overweight (MHOW) and/or metabolically healthy obesity (MHO) increase hyperglycemia risk in a Chinese population with a board age range.

Design: Retrospective cohort study.

Setting: Secondary analysis of data from the DATADRYAD database, comprising health check records of participants from 32 regions and 11 cities in China between 2010 and 2016.

Participants: A total of 47391 metabolically healthy participants with none of metabolic abnormalities were selected.

Outcome measures: Hyperglycemia include incident diabetes and IFG. Diabetes was diagnosed with fasting blood glucose ≥ 7.0 mmol/L and typical clinical symptoms and/or on self-report during follow-up. The FPG level of IFG was from 5.6 to 6.9 mmol/L.

Results: With an average follow-up of 3.06 years, 5274 participants (11.13%) developed hyperglycemia over 144,804 person-years, with an incidence rate of 36.42 per 1000 persons-years. Adjusted model revealed a higher risk of incident hyperglycemia in the MHOW group (HR=1.23, 95%CI: 1.16 to 1.30) and the MHO group (HR=1.49, 95% CI: 1.33 to 1.67) compared with the metabolic healthy normal weight group. With 1 unit increase of BMI, the risk of hyperglycemia increased by 6% (HR = 1.06, 95% CI: 1.04 to 1.07). The stratified analyses and interaction tests showed the robustness of the association, and there were a stronger association in women (*P* for interaction <0.001).

Conclusions: The MHOW and MHO phenotypes were positively associated with higher risk of hyperglycemia in this population. And the association was particularly stronger in women.

Strengths and limitations of this study

- * This retrospective cohort study is representative of the Chinese population, featuring a large sample size and a broad age range.
- * Metabolically healthy status was rigorously defined based on the NCEP ATP-III criteria with none of metabolic abnormalities.
- * Waist circumference was not measured at baseline, limiting the ability to assess the risk of hyperglycemia in individuals with abdominal obesity.
- * Missing information about blood pressure- and lipid-lowing medications may have interfered with appropriate exclusions from the MHOW/MHO groups.

INTRODUCTION

Approximately 537 million adults worldwide have been diagnosed with diabetes mellitus, with over 90% being type 2 diabetes mellitus¹. In addition, prediabetes has emerged as a global epidemic. In 2021, 6.2% of the adult population had impaired fasting glucose (IFG), and 10.6% had impaired glucose tolerance¹. Among Chinese adults, the prevalence of diabetes and prediabetes remained high and increased between 2013 and 2018^{2,3}, with an estimated prevalence of 12.4% for diabetes and 38.1% for prediabetes in 2018³.

The global prevalence of obesity has been steadily rising since the early 1980s⁴, which is one of the key risk factors for diabetes mellitus. However, some obese individuals, classified as having metabolically healthy obesity (MHO), do not present with major cardiovascular risk factors. Nonetheless, the MHO phenotype may progress to metabolically unhealthy obesity over time, increasing the risk of cardiovascular disease and mortality.

A critical issue is the inconsistency in defining MHO. The most common definition of MHO is fewer than two of criteria factors of the metabolic syndrome or fewer than one abnormal factor excluding waist circumference (WC)^{5,6}. In 2021, Zembic A et al have proposed a new definition of MHO based on systolic blood pressure, waist-to-hip ratio and diabetes, and found the cardiovascular mortality risk of the MHO group was not increased when compared the metabolically healthy normal weight (MHNW) individuals⁷. The estimated MHO prevalence was about 50% using ≤ 2 metabolic syndrome factors, or 24% using low HOMA-IR, or 13% when defined with no metabolic abnormality⁸. The relationship between MHO and the risk of diabetes remains a topic of interest. Some studies have suggested that MHO individuals are not at increased risk for diabetes compared to their MHNW counterparts^{9,10}, while others have shown that MHO is indeed associated with a higher risk of diabetes^{11,12}. Moreover, when MHO is defined strictly with no metabolic abnormalities, the association with diabetes risk appears less significant^{11,12}. Recent studies have shown that the multi-organ insulin sensitivity in MHO group was lower than the metabolically healthy and lean group¹³. These inconsistent findings may be partly due to the differing age ranges studied, as most previous research focused on middle-aged individuals under 60 years^{9,10,14-16}, whereas studies in China predominantly examined older populations^{11,12,17}.

Therefore, we aimed to investigate the association between hyperglycemia (including diabetes and IFG) and metabolically healthy individuals without any metabolic abnormalities, based on ATP-III criteria, across young, middle-aged, and elderly groups in a large cohort of the Chinese population.

METHODS

Study design and participants

This study was conducted by the Rich Healthcare Group across 32 sites and 11 cities in China. The subjects who received a health check from 2010 to 2016 were recruited, and the demographic, lifestyle, medical history and family history of chronic disease were collected by questionnaire investigation. As a retrospective cohort study, 685277

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

participants were selected with at least two visits. After excluding the participant who meet the exclusion criteria, a total of 211833 participants (116123 male and 95710 female) were included (in Figure 1). The information of 211,833 individuals was introduced in detail, and the data were download from the “DATADRYAD” database (www.datadryad.org) by Chen et al.¹⁸.

For this study, focusing on metabolically healthy status, we excluded participants with body mass index (BMI) < 18.5 kg/m² (n = 12,081); systolic blood pressure (SBP) ≥ 130 mmHg and/or diastolic blood pressure (DBP) ≥ 85 mmHg, or missing blood pressure values (n = 61,440); fasting plasma glucose (FPG) ≥ 5.6 mmol/L (n = 1,618); triglycerides (TG) ≥ 1.7 mmol/L or missing TG values (n = 28,504); or high-density lipoprotein cholesterol (HDL-C) ≤ 1.04 mmol/L (men) or ≤ 1.29 mmol/L (women) or missing HDL-C values (n = 60,799). A total of 47,391 individuals were included. The flowchart is shown in Figure 1.

Data collection

As described in the original study, basic information was collected via questionnaire, and anthropometric data were measured in a standardized manner. Blood pressure was measured using standard mercury sphygmomanometers. Fasting blood samples were collected to measure glucose, TG, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), HDL-C, aspartate transaminase (AST), and alanine transaminase (ALT) using an autoanalyzer (Beckman 5800).

Definitions of obesity and metabolic health

Body weight was categorized by BMI as follows: normal weight (18.5–23.9 kg/m²), overweight (24.0–27.9 kg/m²), and obese (≥ 28.0 kg/m²). WC was not used due to collinearity with BMI¹⁵. Metabolic health was defined according to the NCEP ATP-III criteria⁵ as the absence of any metabolic abnormalities, which included: SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg; TG ≥ 1.7 mmol/L; FPG ≥ 5.6 mmol/L; and HDL-C ≤ 1.03 mmol/L in men or ≤ 1.29 mmol/L in women.

Based on BMI and metabolic health status, participants were classified into three phenotypes: (1) MHNW, (2) metabolically healthy overweight (MHOW), and (3) MHO.

Outcome measures

The primary of outcome was hyperglycemia, defined as a dichotomous variable (0 = non-hyperglycemia, 1 = hyperglycemia). In this study, hyperglycemia include incident diabetes and IFG. Diabetes was diagnosed with fasting blood glucose ≥7.0 mmol/L and typical clinical symptoms and/or self-report diabetes mellitus during follow-up. The FPG level of IFG was from 5.6 to 6.9 mmol/l based on the American Diabetes Association criteria¹⁹.

Covariates

Covariates were selected based on previous literature^{11, 12, 17, 18, 20, 21}, and included continuous variables (age, ALT, AST, LDL-C, TC, blood urea nitrogen [BUN], and serum creatinine [SCr]) and categorical variables (gender, smoking status, drinking status, and family history of diabetes).

Missing data processing

Missing data were as follows: LDL-C: 26 (0.05%), ALT: 35 (0.07%), AST: 27433

(57.89%), BUN: 354 (0.75%), SCr: 113 (0.24%), drinking status: 34628 (73.07%), and smoking status: 34628 (73.07%), respectively. Multiple imputation was applied for missing continuous variables using a chained equation algorithm with the R's MI package. Missing categorical variables were treated as categorical in the analysis ²².

Statistical analysis

Basic characteristics were presented as mean \pm SD or percentage. Group comparisons were conducted using one-way ANOVA or the Kruskal–Wallis test for continuous variables, and the χ^2 test for categorical variables. The Kaplan–Meier survival method and Cox-proportional hazard model were used to estimate the association of MHOW and MHO for incident hyperglycemia. According to the STROBE statement recommendation ²³, the crude, minor- and full adjustment models were presented. In addition, a restricted cubic spline model was also constructed to assess the dose-response relationship between BMI and hyperglycemia risk.

Subgroup analyses were performed to assess the modifying effects of age, gender, height, and family history of diabetes on the association between BMI and hyperglycemia. Interaction tests were conducted between BMI categories and these subgroup variables. Sensitivity analyses were carried out to assess the robustness of the findings: 1) we did similar analysis after considering diabetes and IFG as separate outcomes; 2) we excluded the participants with missing smoking and drinking status.

All analyses were conducted using R software (version 4.3.3) and Empower Stats (version 4.1). A two-sided P-value < 0.05 was considered statistically significant.

Patient and public involvement

None.

RESULTS

Characteristics of the study participants

A total of 47391 metabolically healthy participants (47.66% male) were finally included. The mean age and BMI were 40.95 ± 11.05 years and 22.48 ± 2.59 kg/m², respectively. During a follow-up period of 3.06 ± 0.95 years, 5,274 participants (11.13%) developed hyperglycemia. The characteristics stratified by BMI categories and the status of blood glucose are presented in Table 1 and Table S1. Participants with higher BMI generally had higher FPG, SBP, DBP, TG, TC, LDL-C, ALT, AST, BUN, and SCr levels, lower HDL-C level, and had a higher proportion of males, current smokers, and current drinkers ($P < 0.001$; Table 1). During follow-up, all characteristics of hyperglycemic participants were different from those of participants without hyperglycemia ($P < 0.05$; Table S1).

Univariate analysis for hyperglycemia in the metabolically healthy population

Table S2 showed that higher age, BMI, FPG, DBP, SBP, TG, TC, LDL, AST, and ALT levels, current drinkers and smokers, and lower HDL-C level were the risk factors of hyperglycemia. Females had a lower risk of hyperglycemia than males. In Figure 2, the Kaplan–Meier curve showed that higher hazards were determined among MHOW and MHO (log-rank test, $P < 0.001$).

Association of MHOW/MHO and hyperglycemia risk among metabolically healthy participants

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In metabolically healthy participants, 5,274 individuals developed hyperglycemia over 144,804 person-years of follow-up, and the overall rate of hyperglycemia was 36.42 per 1000 person-years. The rate of hyperglycemia was 29.35 in MHNW group, 54.07 in MHOW group, and 72.24 in MHO group per 1000 person-years, respectively.

The hazard ratio (HR) and 95% confidence intervals (CI) of the BMI categories on the incidence of hyperglycemia are listed in Table 2. In the crude model, compared with MHNW participants, the risk of hyperglycemia increased 85% in the MHOW group (HR = 1.85, 95% CI:1.75 to 1.97), and 163% in the MHO group (HR = 2.63, 95% CI:2.35 to 2.95), respectively. After adjusting for age, gender, and family history of diabetes, the risk of hyperglycemia in MHOW group and MHO group was still higher than in MHNW group. Furthermore, after adjusting for all the covariates, the relationship was not completely eliminated, with HRs (95% CI) of 1.23 (1.16–1.30) for MHOW and 1.49 (1.33–1.67) for MHO (*P* for trend < 0.001). Moreover, we analyzed the correlation between BMI as a continuous variable and the hyperglycemia risk. The risk of incident of hyperglycemia increased by 6% (HR = 1.06, 95% CI:1.04 to 1.07, *P* < 0.001) with 1 unit increase of BMI.

The restricted cubic spline model showed the risk of hyperglycemia increased gradually with increase in BMI, albeit in a nonlinear manner (*P* < 0.001, *P*-nonlinearity = 0.039, Figure S1).

Subgroup analyses and sensitivity analyses

The results of the stratified analyses and interaction effects are presented in Table 3. The additive interactions between MHOW/MHO and hyperglycemia risk were observed in gender, and stronger correlation was found in female participants. However, no significant interaction was found in age, height or family history of diabetes.

In addition, sensitivity analyses were performed for the risk of diabetes and IFG to confirm the robustness of our results (Table S3). After adjusting for covariates, the HR (95% CI) of incident diabetes was 1.39 (1.05-1.85) for MHOW and 2.91 (1.94-4.37) for MHO (*P* for trend <0.001); the HR (95% CI) of IFG was 1.23 (1.16-1.31) for MHOW and 1.49 (1.32-1.68) for MHO (*P* for trend <0.001). Furthermore, to verify the association of MHOW/MHO and hyperglycemia, the sensitivity analyses were performed as excluding the individuals with missing data of smoking and drinking status (n=12763, Table S4) or AST (n=19955, Table S5). The positive relationship of MHOW/MHO and hyperglycemia risk was still significant.

DISCUSSION

The association between the BMI categories and incident hyperglycemia in the metabolically healthy population was examined in this cohort study. Compared to the MHNW group, both the MHOW and MHO groups exhibited a progressive increase in the risk of hyperglycemia, revealing a clear trend of rising hyperglycemia incidence with higher BMI. This present study suggests that the presence of MHOW/MHO, even with the absence of metabolic risk factors, significantly elevates the incidence of hyperglycemia. Consequently, MHOW and/or MHO should not be treated as a healthy status. Notably, weight management may serve as an effective strategy for

preventing hyperglycemia and its related metabolic diseases among individuals with MHOW or MHO.

The BioSHaRE-EU Healthy Obese Project have shown that the MHO prevalence of was 7%-28% for women, and 2%-19% for men²⁴. The MHO prevalence ranged from 4.2% in a Chinese cohort⁸ to 13.3% among Asian Indians²⁵ and 28.5% in African Americans²⁶. In this study, the prevalence of MHOW (21.93%) and MHO (3.25%) were lower than previous reports, likely due to the strict definition of metabolically healthy status with none of metabolic abnormalities.

Wu et al. highlighted the positive effect of MHO on diabetes based on large numbers of epidemiological studies worldwide⁶. However, the correlation weakens when metabolically healthy status is strictly defined with none of metabolic abnormalities. Notably, the incidence of diabetes increased by 35-67% with one metabolic abnormality addition among metabolic healthy participants²⁷. For example, Feng et al. found that the risk of diabetes increased among MHO individuals in a cohort of 49,702 older adults, but the association was not statistically significant when MHO was defined without ATP-III risk factors¹¹. Similarly, Wei et al. observed an increased diabetes risk among MHO individuals, but this was not statistically significant among those with no metabolic abnormalities in the Dongfeng Tongji cohort study¹². Despite these findings, our study identified a higher risk of hyperglycemia in the MHOW and MHO groups, even with the strict definition of metabolically healthy status as the absence of metabolic abnormalities. However, information about blood pressure- and lipid-lowering medication was missing, and some participants who used these medications would in fact be metabolically unhealthy and should have been excluded. This might partly interpret the positive association of MHOW/MHO and hyperglycemia risk, and the correlation needs to be further explored.

Additionally, we found the positive association of MHOW/MHO phenotype on diabetes and IFG, respectively. In consistent, the risk of diabetes for MHOW or MHO individuals with no metabolic abnormalities was 1.89 and 3.88 times higher, respectively, than in MHNW young men²⁷. These inconsistent results may be attributed to several factors. First, age differences may partly explain the variability in findings. The participants in previous studies had mean ages of 63.2 years¹¹ and 66 (63–71) years¹², whereas the mean age in our study was 40.95 ± 11.05 years. Younger MHO adults may present a higher hyperglycemia risk, as they are more likely to develop metabolic abnormalities in the short term. In contrast, middle-aged MHO individuals may have been overweight or obese for years without developing diabetes or metabolic disorders. Moreover, the concept of “metabolically healthy” status tends to diminish with aging²⁴, which likely accounts for the reduced prevalence of MHOW and MHO in earlier studies^{11,12}.

Notably, the interaction between gender and BMI categories on incident hyperglycemia was significant, with a higher risk observed in women than in men. This finding aligns with some studies^{28,29}, but not all^{30,31}. For example, one cohort study found that the risk of diabetes and IFG was higher in obese women²⁸. Similarly, another prospective case-cohort study noted a strong association between

WC and type 2 diabetes mellitus, particularly in women ²⁹. However, the China Kadoorie Biobank study found greater hazard ratios for diabetes associated with BMI increments in men than in women (P for heterogeneity < 0.001) ³¹. Previous studies have indicated that obesity is a more common and stronger risk factor for diabetes in women ^{32,33}.

The mechanism of positive association between BMI and hyperglycemia incidence in metabolic healthy population still remains unclear. However, it may be partly attributed to increased inflammation and insulin resistance associated with MHO and/or MHO phenotypes. Overweight and obesity are known to induce chronic low-grade inflammation, particularly in insulin-sensitive tissues such as the liver, muscle, and adipose tissues ³⁴. Evidence suggests that chronic inflammation plays a critical role in diabetes development, even among MHO subjects ^{35,36}. The accumulation and infiltration of pro-inflammatory macrophages in adipose tissue are significant contributors to chronic inflammation ³⁷. Pro-inflammatory cytokines, mainly secreted by macrophages, such as tumor necrosis factor (TNF- α) and interleukin-1 beta (IL-1 β), can trigger various signaling pathways that induce insulin resistance. Key signaling pathways include TNF- α /IKK β /NF- κ B and TLR4/NLRP3/caspase-1/IL-1 β , which impair insulin action and modulate pancreatic β -cell mass and function ³⁸.

In addition, the prevalence of non-alcoholic fatty liver disease (NAFLD) is continually increasing due to the obesity epidemic ³⁹. NAFLD is not a consequence of insulin resistance, but it is also a key cause of insulin resistance or diabetes mellitus ⁴⁰. The high prevalence of NAFLD and visceral adiposity was found among the MHO/MHO group, compared with the MHNW group ⁴¹. In a MR analysis of data from the UK Biobank, the positive relationship of higher liver fat content and the risk of type 2 diabetes was observed ⁴². Previous have shown that the increased hepatic lipogenesis and lipodystrophy-like phenotypes with visceral adiposity, resulted in dysregulated hepatokines and dysregulated adipokines, which might be the main cause of insulin resistance ⁴⁰. However, Wei et.al ¹² found the association of the MHO phenotype and increased diabetes incidence did not differ by the presence or absence of NAFLD.

Study strengths and limitations

In addition to its large sample size and broad age range, this study has several strengths. Metabolically healthy individuals were included without any metabolic risk factors, allowing for the independent assessment of the role of BMI in hyperglycemia risk. Furthermore, sensitivity analyses, subgroup analyses, and interaction effects were examined to validate the reliability and stability of the results. However, there are several limitations to our study. First, WC was not measured at baseline, which prevented us from combining WC and BMI to distinguish individuals with abdominal obesity or predict the risk of hyperglycemia among those with abdominal obesity. Second, the missing data on blood pressure- and lipid-lowering medications could have impacted the accuracy of the MHO/MHO categories, as some participants on these medications may have been inappropriately considered metabolically healthy. Third, hyperglycemia prevalence may be underestimated, as random plasma glucose and/or postprandial plasma glucose levels were not collected. Finally, although

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

numerous confounding factors were included, some potential factors may still be unaccounted for, such as physical activity and dietary habits.

CONCLUSION

In conclusion, this study demonstrated that MHOW and MHO are independently and positively associated with the risk of incident hyperglycemia in metabolically healthy adults, with a particularly strong correlation observed in women. Given the unsteady characteristics of metabolically healthy obese phenotypes, these findings underscore the necessity of weight loss, increasing physical activity and diet quality management to reduce hyperglycemia risk and promote overall population health.

For peer review only

Acknowledgements

We thank the field investigators and participants of the Rich Healthcare Group as well as Chen et al. for sharing their database. We thank LetPub (www.letpub.com.cn) for its linguistic assistance during the preparation of this manuscript.

Contributors

QG, QTY and SLJ: study design. QG, BYL, HML, RNX and YRX: data cleaning and analysis. QG, BYL, HML, RNX and YRX: result interpretation. QG: manuscript writing. BYL and HML: manuscript editing. All authors approved the final manuscript. Guarantor is QG.

Funding

This work was supported by the National Natural Science Foundation of China (82204031), Natural Science Foundation of Shandong Province (ZR2021QH188), and the Lin He's Academician Workstation of New Medicine and Clinical Translation in Jining Medical University (JYHL2022MS13).

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

The data used in this analysis can be accessed via the Dryad data repository at <http://datadryad.org/withthefollowingdoi:10.5061/dryad.ft8750v>.

Patient consent

Not required.

Ethics approval

This study was approved by the Rich Healthcare Group Review Board, and the information was retrieved retrospectively.

References

1. International Diabetes Federation. IDF Diabetes Atlas 10th Edition [M]. 2021.
2. Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. *JAMA* 2017;317:2515-23.doi.org/10.1001/jama.2017.7596
3. Wang L, Peng W, Zhao Z, et al. Prevalence and Treatment of Diabetes in China, 2013-2018. *JAMA* 2021;326:2498-506.doi.org/10.1001/jama.2021.22208
4. Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of Obesity in Adults: Latest Trends. *Curr Obes Rep* 2018;7:276-88.doi.org/10.1007/s13679-018-0317-8
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143-421.
6. Wu Q, Xia MF, Gao X. Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus? *World J Diabetes* 2022;13:70-84.doi.org/10.4239/wjd.v13.i2.70
7. Zembic A, Eckel N, Stefan N, et.al. An Empirically Derived Definition of Metabolically Healthy Obesity Based on Risk of Cardiovascular and Total Mortality. *JAMA Netw Open*. 2021;4(5):e218505.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

doi:10.1001/jamanetworkopen.2021.8505

8. Schulze MB, Stefan N. Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications. *Nat Rev Endocrinol*. 2024;20(11):633-646. doi: 10.1038/s41574-024-01008-5.
9. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. *J Clin Endocrinol Metab* 2006;91:2906-12.doi.org/10.1210/jc.2006-0594
10. Appleton SL, Seaborn CJ, Visvanathan R, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. *Diabetes Care* 2013;36:2388-94.doi.org/10.2337/dc12-1971
11. Feng S, Gong X, Liu H, et al. The Diabetes Risk and Determinants of Transition from Metabolically Healthy to Unhealthy Phenotypes in 49,702 Older Adults: 4-Year Cohort Study. *Obesity (Silver Spring)* 2020;28:1141-8.doi.org/10.1002/oby.22800
12. Wei Y, Wang J, Han X, et al. Metabolically healthy obesity increased diabetes incidence in a middle-aged and elderly Chinese population. *Diabetes Metab Res Rev* 2020;36:e3202.doi.org/10.1002/dmrr.3202
13. Petersen MC, Smith GI, Palacios HH, et al. Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity. *Cell Metab*. 2024;36(4):745-61.e5. doi:10.1016/j.cmet.2024.03.002
14. Luo D, Liu F, Li X, et al. Comparison of the effect of 'metabolically healthy but obese' and 'metabolically abnormal but not obese' phenotypes on development of diabetes and cardiovascular disease in Chinese. *Endocrine* 2015;49:130-8.doi.org/10.1007/s12020-014-0444-2
15. Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. *Eur Heart J* 2015;36:551-9.doi.org/10.1093/eurheartj/ehu123
16. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. *Obes Rev* 2014;15:504-15.doi.org/10.1111/obr.12157
17. Liu M, Tang R, Wang J, He Y. Distribution of metabolic/obese phenotypes and association with diabetes: 5 years' cohort based on 22,276 elderly. *Endocrine* 2018;62:107-15.doi.org/10.1007/s12020-018-1672-7
18. Chen Y, Zhang XP, Yuan J, et al. Association of body mass index and age with incident diabetes in Chinese adults: a population-based cohort study. *BMJ Open* 2018;8:e021768.doi.org/10.1136/bmjopen-2018-021768
19. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. *Diabetes Care* 2022;45:S17-s38.doi.org/10.2337/dc22-S002
20. Ye J, Guo K, Li X, Yang L, Zhou Z. The Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. *J Clin Endocrinol Metab* 2023;108:2240-7.doi.org/10.1210/clinem/dgad152
21. Wang B, Zhang M, Wang S, et al. Dynamic status of metabolically healthy overweight/obesity and metabolically unhealthy and normal weight and the risk of type 2 diabetes mellitus: A cohort study of a rural adult Chinese population. *Obes Res Clin Pract* 2018;12:61-71.doi.org/10.1016/j.orcp.2017.10.005

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

22. Erviti J, Alonso A, Oliva B, et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. *BMJ Open* 2013;3.doi.org/10.1136/bmjopen-2012-002091

23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg.* 2014;12:1495-9.doi.org/10.1016/j.ijssu.2014.07.013

24. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. *BMC Endocr Disord* 2014;14:9.doi.org/10.1186/1472-6823-14-9

25. Geetha L, Deepa M, Anjana RM, Mohan V. Prevalence and clinical profile of metabolic obesity and phenotypic obesity in Asian Indians. *J Diabetes Sci Technol* 2011;5:439-46.doi.org/10.1177/193229681100500235

26. Cherqaoui R, Kassim TA, Kwagyan J, et al. The metabolically healthy but obese phenotype in African Americans. *J Clin Hypertens (Greenwich)* 2012;14:92-6.doi.org/10.1111/j.1751-7176.2011.00565.x

27. Twig G, Afek A, Derazne E, et al. Diabetes risk among overweight and obese metabolically healthy young adults. *Diabetes Care* 2014;37:2989-95.doi.org/10.2337/dc14-0869

28. Vaidya A, Cui L, Sun L, et al. A prospective study of impaired fasting glucose and type 2 diabetes in China: The Kailuan study. *Medicine (Baltimore)* 2016;95:e5350.doi.org/10.1097/md.0000000000005350

29. Langenberg C, Sharp SJ, Schulze MB, et al. Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. *PLoS Med* 2012;9:e1001230.doi.org/10.1371/journal.pmed.1001230

30. Zhu Y, Hu C, Lin L, et al. Obesity mediates the opposite association of education and diabetes in Chinese men and women: Results from the REACTION study. *J Diabetes* 2022;14:739-48.doi.org/10.1111/1753-0407.13325

31. Bragg F, Tang K, Guo Y, et al. Associations of General and Central Adiposity With Incident Diabetes in Chinese Men and Women. *Diabetes Care.* 2018;41:494-502.doi.org/10.2337/dc17-1852

32. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev* 2016;37:278-316.doi.org/10.1210/er.2015-1137

33. Logue J, Walker JJ, Colhoun HM, et al. Do men develop type 2 diabetes at lower body mass indices than women? *Diabetologia.* 2011;54:3003-6.doi.org/10.1007/s00125-011-2313-3

34. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. *Diabetes Res Clin Pract.* 2014;105:141-50.doi.org/10.1016/j.diabres.2014.04.006

35. Zhao R, Tang D, Yi S, et al. Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. *PLoS One.* 2014;9:e85770.doi.org/10.1371/journal.pone.0085770

36. Jung CH, Lee MJ, Kang YM, et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. *J Clin Endocrinol Metab.* 2015;100:934-41.doi.org/10.1210/jc.2014-3885

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

- 496 **37.** Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-Inflammation and
497 Metabolic Reprogramming of Macrophages in Diabetes and Obesity: The Importance of
498 Metabolites. *Front Immunol.* 2021;12:746151. doi.org/10.3389/fimmu.2021.746151
- 499 **38.** Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and
500 related disorders. *Immunity.* 2022;55:31-55. doi.org/10.1016/j.immuni.2021.12.013
- 501 **39.** European Association for the Study of the Liver (EASL). Electronic address:
502 easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD);
503 European Association for the Study of Obesity (EASO); European Association for the
504 Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the
505 management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J*
506 *Hepatol.* 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031
- 507 **40.** Stefan N, Schick F, Birkenfeld AL, Häring HU, White MF. The role of hepatokines in
508 NAFLD. *Cell Metab.* 2023;35(2):236-52. doi:10.1016/j.cmet.2023.01.006
- 509 **41.** Stefan N, Schick F, Häring HU. Causes, Characteristics, and Consequences of
510 Metabolically Unhealthy Normal Weight in Humans. *Cell Metab.* 2017;26(2):292-300.
511 doi:10.1016/j.cmet.2017.07.008
- 512 **42.** Martin S, Sorokin EP, Thomas EL, et al. Estimating the Effect of Liver and Pancreas
513 Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study.
514 *Diabetes Care.* 2022;45(2):460-8. doi:10.2337/dc21-1262
- 515
516
517
518
519
520
521
522

Table 1. Characteristics of study participants, stratified by BMI group

Variables	Total	MHNW	MHOW	MHO	P-value
N	47391	34920	10932	1539	
Age (years)	40.95 ± 11.05	40.10 ± 10.70	43.38 ± 11.60	42.93 ± 12.07	<0.001
Male, n (%)	22586 (47.66)	14124 (40.45)	7369 (67.41)	1093 (71.02)	<0.001
BMI (kg/m ²)	22.48 ± 2.59	21.25 ± 1.48	25.41 ± 1.05	29.56 ± 1.69	<0.001
FPG (mmol/L)	4.82 ± 0.52	4.78 ± 0.52	4.92 ± 0.52	4.99 ± 0.54	<0.001
SBP (mmHg)	110.88 ± 10.24	109.65 ± 10.30	114.07 ± 9.31	116.26 ± 8.63	<0.001
DBP (mmHg)	69.23 ± 7.47	68.45 ± 7.43	71.22 ± 7.14	72.63 ± 7.13	<0.001
TG (mmol/L)	0.92 ± 0.34	0.87 ± 0.32	1.06 ± 0.33	1.16 ± 0.32	<0.001
TC (mmol/L)	4.69 ± 0.80	4.65 ± 0.80	4.79 ± 0.80	4.84 ± 0.79	<0.001
HDL-C (mmol/L)	1.50 ± 0.26	1.53 ± 0.27	1.42 ± 0.23	1.38 ± 0.21	<0.001
LDL-C (mmol/L)	2.70 ± 0.62	2.66 ± 0.61	2.80 ± 0.62	2.85 ± 0.63	<0.001
ALT (mmol/L)	22.49 ± 10.50	21.66 ± 10.15	24.46 ± 10.94	27.46 ± 11.82	<0.001
AST (mmol/L)	20.22 ± 18.34	18.05 ± 16.65	25.39 ± 20.72	32.80 ± 23.65	<0.001
BUN (mmol/L)	4.63 ± 1.16	4.56 ± 1.14	4.84 ± 1.17	4.91 ± 1.13	<0.001
SCr (mmol/L)	68.87 ± 15.47	67.05 ± 14.79	73.92 ± 16.32	74.36 ± 14.91	<0.001
Smoking status, n (%)					<0.001

Current smoker	2049 (4.32)	1277 (3.66)	667 (6.10)	105 (6.82)	<0.001
Ever smoker	493 (1.04)	284 (0.81)	181 (1.66)	28 (1.82)	
Never smoker	10221 (21.57)	7600 (21.76)	2313 (21.16)	308 (20.01)	
Drinking status, n (%)					0.874
Current drinker	249 (0.53)	144 (0.41)	85 (0.78)	20 (1.30)	
Ever drinker	2117 (4.47)	1274 (3.65)	740 (6.77)	103 (6.69)	
Never drinker	10397 (21.94)	7743 (22.17)	2336 (21.37)	318 (20.66)	
Family history of diabetes, n (%)					
Yes	1061 (2.24)	789 (2.26)	239 (2.19)	33 (2.14)	

Table 2. Relationship between BMI categories and risk of hyperglycemia among metabolically healthy participants

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
Hyperglycemia				
BMI	5274/47391	1.14 (1.13, 1.15)	1.10 (1.09, 1.11)	1.06 (1.04, 1.07)
MHNW	3139/34920	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	1798/10932	1.85 (1.75, 1.97)	1.51 (1.42, 1.60)	1.23 (1.16, 1.30)
MHO	337/1539	2.63 (2.35, 2.95)	2.10 (1.88, 2.36)	1.49 (1.33, 1.67)
P for trend		<0.001	<0.001	<0.001

Model I: adjusted for age, gender and family history of diabetes;
Model II: further adjusted for baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

Table 3. Multivariate-adjusted HR (95% CI) of hyperglycemia among BMI categories in stratified analyses

	MHNW	MHOW	MHO	<i>P</i> interaction
Gender				<0.001
Male	1.00 (Ref.)	1.11 (1.03, 1.20)	1.32 (1.15, 1.51)	
Female	1.00 (Ref.)	1.43 (1.29, 1.58)	1.88 (1.52, 2.32)	
Age (years)				0.534
< 40	1.00 (Ref.)	1.32 (1.17, 1.48)	1.51 (1.21, 1.89)	
≥ 40	1.00 (Ref.)	1.22(1.13, 1.31)	1.53 (1.34, 1.75)	
Family history of diabetes				0.290
yes	1.00 (Ref.)	1.23 (1.15, 1.30)	1.46 (1.30, 1.65)	
no	1.00 (Ref.)	1.05 (0.71, 1.55)	2.12 (1.07, 4.19)	
Height (cm)		1.31 (1.16, 1.47)	1.75 (1.38, 2.21)	0.056
≤ 161.90	1.00 (Ref.)	1.31 (1.16, 1.47)	1.75 (1.38, 2.21)	
162.00-169.90	1.00 (Ref.)	1.26 (1.13, 1.40)	1.33 (1.07, 1.64)	
≥ 170.00	1.00 (Ref.)	1.15 (1.04, 1.26)	1.50 (1.26, 1.78)	

Adjusted for gender (except gender subgroup), age (except age subgroup), family history of diabetes (except “family history of diabetes” subgroup), and baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

FIGURE LEGENDS

Figure 1. Study flowchart.

Figure 2. Kaplan–Meier curves for cumulative hazard ratios of incident risk of hyperglycemia. The figure shows that the cumulative risk of incident hyperglycemia was markedly different among the BMI categories (log-rank test, $P < 0.001$) and increased gradually with increasing BMI, resulting in maximum risk of prediabetes in the MHO group.

Supplemental Figure S1. Restricted cubic spline analyses illustrating the dose-response relationship between BMI and incidence of hyperglycemia.




Figure 1. Study flow chart.

90x90mm (300 x 300 DPI)




Figure 2. Kaplan–Meier curves for cumulative hazard ratios of incident risk of hyperglycemia. The figure shows that the cumulative risk of incident hyperglycemia was markedly different among the BMI categories (log-rank test, $P < 0.001$) and increased gradually with increasing BMI, resulting in maximum risk of prediabetes in the MHO group.

90x90mm (300 x 300 DPI)

Table S1
The characteristics of the study participants with/without hyperglycemia

Variables	Non-hyperglycemia	Hyperglycemia	P-value
N	42117	5274	
Age (years)	40.25 ± 10.66	46.54 ± 12.48	<0.001
Male, n (%)	19401 (46.06)	3185 (60.39)	<0.001
BMI (kg/m ²)	22.35 ± 2.53	23.48 ± 2.81	<0.001
FPG (mmol/L)	4.77 ± 0.51	5.20 ± 0.51	<0.001
SBP (mmHg)	110.53 ± 10.26	113.72 ± 9.70	<0.001
DBP (mmHg)	69.01 ± 7.48	70.95 ± 7.21	<0.001
TG (mmol/L)	0.91 ± 0.33	1.01 ± 0.34	<0.001
TC (mmol/L)	4.67 ± 0.80	4.83 ± 0.83	<0.001
HDL-C (mmol/L)	1.51 ± 0.26	1.46 ± 0.25	<0.001
LDL-C (mmol/L)	2.69 ± 0.62	2.79 ± 0.63	<0.001
ALT (mmol/L)	22.35 ± 10.46	23.63 ± 10.71	<0.001
AST (mmol/L)	19.89 ± 18.03	22.92 ± 20.38	<0.001
BUN (mmol/L)	4.60 ± 1.15	4.88 ± 1.18	<0.001
SCr (mmol/L)	68.44 ± 15.46	72.27 ± 15.09	<0.001
Smoking status, n (%)			<0.001
Current smoker	1741 (4.13)	308 (5.84)	
Ever smoker	441 (1.05)	52 (0.99)	
Never smoker	9171 (21.78)	1050 (19.91)	
Drinking status, n (%)			0.003
Current drinker	211 (0.50)	38 (0.72)	
Ever drinker	1844 (4.38)	273 (5.18)	
Never drinker	9298 (22.08)	1099 (20.84)	
Family history of diabetes, n (%)			0.039
Yes	922 (2.19)	139 (2.64)	

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Table S 2

The results of univariate analysis for the risk factors of hyperglycemia

Covariables	HR (95%CI)	P-value
Age (years)	1.04 (1.03, 1.04)	<0.001
Gender		<0.001
Male	Ref.	
Female	0.60 (0.57, 0.64)	
FPG (mmol/L)	5.95 (5.63, 6.28)	<0.001
SBP (mmHg)	1.03 (1.03, 1.03)	<0.001
DBP (mmHg)	1.03 (1.02, 1.03)	<0.001
TG (mmol/L)	2.34 (2.17, 2.53)	<0.001
TC (mmol/L)	1.17 (1.13, 1.20)	<0.001
HDL-C (mmol/L)	0.62 (0.55, 0.68)	<0.001
LDL-C (mmol/L)	1.31 (1.26, 1.37)	<0.001
ALT (mmol/L)	1.00 (1.00, 1.00)	<0.001
AST (mmol/L)	1.01 (1.00, 1.01)	<0.001
BUN (mmol/L)	1.16 (1.14, 1.18)	<0.001
SCr (mmol/L)	1.01 (1.00, 1.01)	<0.001
Smoking status, n (%)		<0.001
Never smoker	Ref.	
Ever smoker	0.93 (0.70, 1.23)	
Current smoker	1.40 (1.23, 1.59)	
Drinking status, n (%)		<0.001
Never drinker	Ref.	
Ever drinker	1.15 (1.01, 1.31)	
Current drinker	1.56 (1.13, 2.15)	
Family history of diabetes		0.500
No	Ref.	
Yes	1.06 (0.90, 1.26)	

Table S3
Relationship between BMI categories and the risk of diabetes/IFG among the metabolically healthy participants

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
Diabetes				
BMI	239/47391	1.24 (1.20, 1.28)	1.19 (1.14, 1.24)	1.14 (1.09, 1.18)
MHNW	116/34920	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	91/10932	2.53 (1.92, 3.32)	1.78 (1.35, 2.36)	1.39 (1.05, 1.85)
MHO	32/1539	6.84 (4.62, 10.11)	4.55 (3.05, 6.78)	2.91 (1.94, 4.37)
<i>P</i> for trend		<0.001	<0.001	<0.001
IFG				
BMI	5035/47152	1.14 (1.13, 1.15)	1.10 (1.09, 1.11)	1.05 (1.04, 1.07)
MHNW	3023/34804	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	1707/10841	1.85 (1.74, 1.96)	1.51 (1.42, 1.61)	1.23 (1.16, 1.31)

MHO	305/1507	2.54 (2.26, 2.86)	2.07 (1.83, 2.33)	1.49 (1.32, 1.68)
<i>P</i> for trend		<0.001	<0.001	<0.001

Model I: adjusted age, gender and the family history of diabetes;

Model II: further adjusted baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

Table S4

Relationship between BMI categories and the risk of hyperglycemia among the metabolically healthy participants without missing data of smoking and drinking status

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
BMI	1410/12763	1.12 (1.10, 1.14)	1.09 (1.07, 1.11)	1.05 (1.03, 1.07)
MHNW	844/9161	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	485/3161	1.73 (1.55, 1.94)	1.43 (1.27, 1.60)	1.16 (1.03, 1.30)
MHO	81/441	2.14 (1.70, 2.69)	1.75 (1.39, 2.21)	1.28 (1.01, 1.61)
<i>P</i> for trend		<0.001	<0.001	<0.001

Model I: adjusted age, gender and the family history of diabetes;

Model II: further adjusted baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

Table S5

Relationship between BMI categories and the risk of hyperglycemia among the metabolically healthy participants without missing data of AST

	Case/N	Crude Model (HR, 95% CI)	Model I (HR, 95% CI)	Model II (HR, 95% CI)
BMI	2717/19955	1.14 (1.12, 1.15)	1.11 (1.09, 1.12)	1.05 (1.04, 1.07)
MHNW	1604/14558	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
MHOW	945/4742	1.85 (1.70, 2.01)	1.54 (1.42, 1.67)	1.23 (1.13, 1.34)
MHO	168/655	2.51 (2.15, 2.95)	2.06 (1.75, 2.46)	1.49 (1.27, 1.76)
<i>P</i> for trend		<0.001	<0.001	<0.001

Model I: adjusted for age, gender and family history of diabetes;

Model II: further adjusted for baseline FPG, ALT, AST, BUN, SCr, smoking status and drinking status.

For peer review only




Figure S1. Restricted cubic spline analyses illustrating the dose-response relationship between BMI and incidence of hyperglycemia.

90x90mm (300 x 300 DPI)